Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27037817,clearance,"The population estimates (95 % CI) per 70 kg bodyweight were: clearance 36.2 (33.3-41.1) l/h, central volume of distribution 84.3 (70.3-91.4) l, intercompartmental clearance 82.8 (63.6-136.6) l/h, peripheral volume of distribution 114 (95-149) l, and terminal half-life 4.4 (3.6-5.3) h.",Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037817/),[l] / [h],36.2,1401,DB00633,Dexmedetomidine
,27037817,central volume of distribution,"The population estimates (95 % CI) per 70 kg bodyweight were: clearance 36.2 (33.3-41.1) l/h, central volume of distribution 84.3 (70.3-91.4) l, intercompartmental clearance 82.8 (63.6-136.6) l/h, peripheral volume of distribution 114 (95-149) l, and terminal half-life 4.4 (3.6-5.3) h.",Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037817/),l,84.3,1402,DB00633,Dexmedetomidine
,27037817,intercompartmental clearance,"The population estimates (95 % CI) per 70 kg bodyweight were: clearance 36.2 (33.3-41.1) l/h, central volume of distribution 84.3 (70.3-91.4) l, intercompartmental clearance 82.8 (63.6-136.6) l/h, peripheral volume of distribution 114 (95-149) l, and terminal half-life 4.4 (3.6-5.3) h.",Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037817/),[l] / [h],82.8,1403,DB00633,Dexmedetomidine
,27037817,peripheral volume of distribution,"The population estimates (95 % CI) per 70 kg bodyweight were: clearance 36.2 (33.3-41.1) l/h, central volume of distribution 84.3 (70.3-91.4) l, intercompartmental clearance 82.8 (63.6-136.6) l/h, peripheral volume of distribution 114 (95-149) l, and terminal half-life 4.4 (3.6-5.3) h.",Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037817/),l,114,1404,DB00633,Dexmedetomidine
,27037817,terminal half-life,"The population estimates (95 % CI) per 70 kg bodyweight were: clearance 36.2 (33.3-41.1) l/h, central volume of distribution 84.3 (70.3-91.4) l, intercompartmental clearance 82.8 (63.6-136.6) l/h, peripheral volume of distribution 114 (95-149) l, and terminal half-life 4.4 (3.6-5.3) h.",Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037817/),h,4.4,1405,DB00633,Dexmedetomidine
,25066475,elimination half-life,Dexmedetomidine concentrations decreased rapidly (elimination half-life of 8.03 ± 0.84 min).,Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25066475/),min,8.03,2840,DB00633,Dexmedetomidine
,25066475,Time of last detection,Time of last detection varied from 30 to 60 min.,Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25066475/),min,30 to 60,2841,DB00633,Dexmedetomidine
,29661383,peak plasma concentration,An average peak plasma concentration of 199 pg ml-1 was achieved 46 min after 1 μg kg-1 dosing and 355 pg ml-1 was achieved 47 min after 2 μg kg-1 dosing.,Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661383/),[pg] / [ml],199,5605,DB00633,Dexmedetomidine
,29661383,peak plasma concentration,An average peak plasma concentration of 199 pg ml-1 was achieved 46 min after 1 μg kg-1 dosing and 355 pg ml-1 was achieved 47 min after 2 μg kg-1 dosing.,Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661383/),[pg] / [ml],355,5606,DB00633,Dexmedetomidine
,29661383,bioavailability,Typical bioavailability was 83.8% (95% confidence interval 69.5-98.1%).,Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661383/),%,83.8,5607,DB00633,Dexmedetomidine
,29661383,arterial plasma concentrations,"Mean arterial plasma concentrations of dexmedetomidine in infants and toddlers approached 100 pg ml-1, the low end reported for sedative efficacy, within 20 min of an atomised intranasal administration of 1 μg kg-1.",Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661383/),[pg] / [ml],100,5608,DB00633,Dexmedetomidine
,29661383,overall bioavailability,"Peak plasma concentrations with both doses were reached within 47 min of intranasal administration, with an overall bioavailability of 84%.",Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661383/),%,84,5609,DB00633,Dexmedetomidine
,31556717,maximum plasma concentration,"For the OTM route, the mean ± SD maximum plasma concentration was 3.8 ± 1.3 ng/mL, which was detected 73 ± 33 minutes after administration.",Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),[ng] / [ml],3.8,5797,DB00633,Dexmedetomidine
,31556717,maximum concentration,"The mean maximum concentration for the IV dose, when extrapolated to the time of administration, was 18.6 ± 3.3 ng/mL.",Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),[ng] / [ml],18.6,5798,DB00633,Dexmedetomidine
,31556717,terminal-phase half-life,"The mean terminal-phase half-life was 152 ± 146 minutes and 36 ± 6 minutes for OTM and IV administration, respectively.",Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),min,152,5799,DB00633,Dexmedetomidine
,31556717,terminal-phase half-life,"The mean terminal-phase half-life was 152 ± 146 minutes and 36 ± 6 minutes for OTM and IV administration, respectively.",Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),min,36,5800,DB00633,Dexmedetomidine
,31556717,total clearance,"After IV administration, total clearance was 8.0 ± 1.6 mL/min/kg and volume of distribution at steady state was 371 ± 72 mL/kg.",Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),[ml] / [kg·min],8.0,5801,DB00633,Dexmedetomidine
,31556717,volume of distribution at steady state,"After IV administration, total clearance was 8.0 ± 1.6 mL/min/kg and volume of distribution at steady state was 371 ± 72 mL/kg.",Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),[ml] / [kg],371,5802,DB00633,Dexmedetomidine
,31556717,Bioavailability,Bioavailability for OTM administration of dexmedetomidine was 11.2 ± 4.5%.,Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556717/),%,11.2,5803,DB00633,Dexmedetomidine
,31581476,clearance,"The population estimates (95% confidence interval) per 70 kg body weight were as follows: clearance of 81.0 (72.9-90.9) L/h, central volume of distribution of 64.2 (50.6-81.0) L, intercompartment clearance of 116.4 (90.6-156.0) L/h, and peripheral volume of distribution of 167 (132-217) L.",A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581476/),[l] / [h],81.0,6567,DB00633,Dexmedetomidine
,31581476,central volume of distribution,"The population estimates (95% confidence interval) per 70 kg body weight were as follows: clearance of 81.0 (72.9-90.9) L/h, central volume of distribution of 64.2 (50.6-81.0) L, intercompartment clearance of 116.4 (90.6-156.0) L/h, and peripheral volume of distribution of 167 (132-217) L.",A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581476/),l,64.2,6568,DB00633,Dexmedetomidine
,31581476,intercompartment clearance,"The population estimates (95% confidence interval) per 70 kg body weight were as follows: clearance of 81.0 (72.9-90.9) L/h, central volume of distribution of 64.2 (50.6-81.0) L, intercompartment clearance of 116.4 (90.6-156.0) L/h, and peripheral volume of distribution of 167 (132-217) L.",A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581476/),[l] / [h],116.4,6569,DB00633,Dexmedetomidine
,31581476,peripheral volume of distribution,"The population estimates (95% confidence interval) per 70 kg body weight were as follows: clearance of 81.0 (72.9-90.9) L/h, central volume of distribution of 64.2 (50.6-81.0) L, intercompartment clearance of 116.4 (90.6-156.0) L/h, and peripheral volume of distribution of 167 (132-217) L.",A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581476/),l,167,6570,DB00633,Dexmedetomidine
,11682398,volume of distribution at steady state,"There was no difference between Renal Disease and Control groups in either volume of distribution at steady state (1.81 +/- 0.55 and 1.54 +/- 0.08 L/kg, respectively; mean +/- SD) or elimination clearance (12.5 +/- 4.6 and 8.9 +/- 0.7 mL x min(-1) x kg(-1), respectively).",The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11682398/),[l] / [kg],1.81,6598,DB00633,Dexmedetomidine
,11682398,volume of distribution at steady state,"There was no difference between Renal Disease and Control groups in either volume of distribution at steady state (1.81 +/- 0.55 and 1.54 +/- 0.08 L/kg, respectively; mean +/- SD) or elimination clearance (12.5 +/- 4.6 and 8.9 +/- 0.7 mL x min(-1) x kg(-1), respectively).",The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11682398/),[l] / [kg],1.54,6599,DB00633,Dexmedetomidine
,11682398,elimination clearance,"There was no difference between Renal Disease and Control groups in either volume of distribution at steady state (1.81 +/- 0.55 and 1.54 +/- 0.08 L/kg, respectively; mean +/- SD) or elimination clearance (12.5 +/- 4.6 and 8.9 +/- 0.7 mL x min(-1) x kg(-1), respectively).",The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11682398/),[ml] / [kg·min],12.5,6600,DB00633,Dexmedetomidine
,11682398,elimination clearance,"There was no difference between Renal Disease and Control groups in either volume of distribution at steady state (1.81 +/- 0.55 and 1.54 +/- 0.08 L/kg, respectively; mean +/- SD) or elimination clearance (12.5 +/- 4.6 and 8.9 +/- 0.7 mL x min(-1) x kg(-1), respectively).",The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11682398/),[ml] / [kg·min],8.9,6601,DB00633,Dexmedetomidine
,11682398,elimination half-life,"However, elimination half-life was shortened in the Renal Disease group (113.4 +/- 11.3 vs 136.5 +/- 13.0 min; P < 0.05).",The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11682398/),min,113.4,6602,DB00633,Dexmedetomidine
,11682398,elimination half-life,"However, elimination half-life was shortened in the Renal Disease group (113.4 +/- 11.3 vs 136.5 +/- 13.0 min; P < 0.05).",The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11682398/),min,136.5,6603,DB00633,Dexmedetomidine
,19708909,clearance (CL),"Population parameter estimates (between subject variability) for a two-compartment model were clearance (CL) 42.1 (CV 30.9%) lx h(-1) x 70 kg(-1), central volume of distribution (V1) 56.3 (61.3%) l.70 kg(-1), inter-compartment clearance (Q) 78.3 (37.0%) l x h(-1) x 70 kg(-1) and peripheral volume of distribution (V2) 69.0 (47.0%) l.70 kg(-1).",Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708909/),[l] / [70·h·kg],42.1,8892,DB00633,Dexmedetomidine
,19708909,central volume of distribution (V1),"Population parameter estimates (between subject variability) for a two-compartment model were clearance (CL) 42.1 (CV 30.9%) lx h(-1) x 70 kg(-1), central volume of distribution (V1) 56.3 (61.3%) l.70 kg(-1), inter-compartment clearance (Q) 78.3 (37.0%) l x h(-1) x 70 kg(-1) and peripheral volume of distribution (V2) 69.0 (47.0%) l.70 kg(-1).",Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708909/),[l] / [70·kg],56.3,8893,DB00633,Dexmedetomidine
,19708909,inter-compartment clearance (Q),"Population parameter estimates (between subject variability) for a two-compartment model were clearance (CL) 42.1 (CV 30.9%) lx h(-1) x 70 kg(-1), central volume of distribution (V1) 56.3 (61.3%) l.70 kg(-1), inter-compartment clearance (Q) 78.3 (37.0%) l x h(-1) x 70 kg(-1) and peripheral volume of distribution (V2) 69.0 (47.0%) l.70 kg(-1).",Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708909/),[l] / [70·h·kg],78.3,8894,DB00633,Dexmedetomidine
,19708909,peripheral volume of distribution (V2),"Population parameter estimates (between subject variability) for a two-compartment model were clearance (CL) 42.1 (CV 30.9%) lx h(-1) x 70 kg(-1), central volume of distribution (V1) 56.3 (61.3%) l.70 kg(-1), inter-compartment clearance (Q) 78.3 (37.0%) l x h(-1) x 70 kg(-1) and peripheral volume of distribution (V2) 69.0 (47.0%) l.70 kg(-1).",Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708909/),[l] / [70·kg],69.0,8895,DB00633,Dexmedetomidine
,19708909,Clearance,Clearance increases from 18.2 l x h(-1) x 70 kg(-1) at birth in a term neonate to reach 84.5% of the mature value by 1 year of age.,Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708909/),[l] / [70·h·kg],18.2,8896,DB00633,Dexmedetomidine
,19708909,therapeutic concentration,Simulation of published infusion rates that provide adequate sedation for intensive care patients found a target therapeutic concentration of between 0.4 and 0.8 microg x l(-1).,Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708909/),[μg] / [l],0.4 and 0.8,8897,DB00633,Dexmedetomidine
,32500578,central volume of distribution,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),l,22.50,12708,DB00633,Dexmedetomidine
,32500578,peripheral volume of distribution,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),l,86.1,12709,DB00633,Dexmedetomidine
,32500578,systemic clearance,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),[l] / [h],34.7,12710,DB00633,Dexmedetomidine
,32500578,distribution clearance,"Typical values of the central and peripheral volume of distribution and the systemic and distribution clearance for a theoretical adult patient were central volume of distribution = 22.50 L, peripheral volume of distribution = 86.1 L, systemic clearance = 34.7 L/h, and distribution clearance = 40.8 L/h.",Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32500578/),[l] / [h],40.8,12711,DB00633,Dexmedetomidine
,22271297,clearance,"Using a Bayesian hierarchical nonlinear mixture model, estimated dexmedetomidine clearance was 49.1 L/h (posterior mean; 95% credible interval 41.4-57.6 L/h).",CYP2A6 genetic variation and dexmedetomidine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271297/),[l] / [h],49.1,14894,DB00633,Dexmedetomidine
,20418300,clearance,"Infants demonstrated a clearance of 28.1 mL/min/kg(0.75), intercompartmental clearance of 93.4 mL/min/kg(0.75), central volume of distribution of 1.2 L/kg, and peripheral volume of distribution of 1.5 L/kg.",Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418300/),[ml] / [kg·min],28.1,18970,DB00633,Dexmedetomidine
,20418300,intercompartmental clearance,"Infants demonstrated a clearance of 28.1 mL/min/kg(0.75), intercompartmental clearance of 93.4 mL/min/kg(0.75), central volume of distribution of 1.2 L/kg, and peripheral volume of distribution of 1.5 L/kg.",Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418300/),[ml] / [kg·min],93.4,18971,DB00633,Dexmedetomidine
,20418300,central volume of distribution,"Infants demonstrated a clearance of 28.1 mL/min/kg(0.75), intercompartmental clearance of 93.4 mL/min/kg(0.75), central volume of distribution of 1.2 L/kg, and peripheral volume of distribution of 1.5 L/kg.",Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418300/),[l] / [kg],1.2,18972,DB00633,Dexmedetomidine
,20418300,peripheral volume of distribution,"Infants demonstrated a clearance of 28.1 mL/min/kg(0.75), intercompartmental clearance of 93.4 mL/min/kg(0.75), central volume of distribution of 1.2 L/kg, and peripheral volume of distribution of 1.5 L/kg.",Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418300/),[l] / [kg],1.5,18973,DB00633,Dexmedetomidine
,20418300,CIVI,Initial loading doses in the range of 0.35 to 1 microg/kg over 10 minutes and CIVI of 0.25 to 0.75 microg/kg/h were well tolerated in this infant population.,Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418300/),[μg] / [h·kg],0.25 to 0.75,18974,DB00633,Dexmedetomidine
,8098190,percentage bioavailability,The percentage bioavailability of dexmedetomidine administered intramuscularly compared with the same dose administered intravenously was 73 +/- 11% (mean +/- SD).,The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098190/),%,73,23976,DB00633,Dexmedetomidine
,8098190,time to peak concentration,"After intramuscular administration, the mean time to peak concentration was 12 min (range 2-60 min) and the mean peak concentration was 0.81 +/- 0.27 ng/ml.",The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098190/),min,12,23977,DB00633,Dexmedetomidine
,8098190,peak concentration,"After intramuscular administration, the mean time to peak concentration was 12 min (range 2-60 min) and the mean peak concentration was 0.81 +/- 0.27 ng/ml.",The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098190/),[ng] / [ml],0.81,23978,DB00633,Dexmedetomidine
,19207899,target plasma concentrations,Twelve children received dexmedetomidine 1 microg x kg(-1) given over 10 min as well as a continuous infusion of propofol delivered by a computer-assisted target-controlled infusion (TCI) system with target plasma concentrations ranging from 2.8 to 4.0 microg x ml(-1) (DEX group).,Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19207899/),[μg] / [ml],2.8 to 4.0,25664,DB00633,Dexmedetomidine
,19207899,EC50,"The EC50 +/- SE values in the control and DEX groups were 3.7 +/- 0.4 microg x ml(-1) and 3.5 +/- 0.2 microg x ml(-1), respectively.",Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19207899/),[μg] / [ml],3.7,25665,DB00633,Dexmedetomidine
,19207899,EC50,"The EC50 +/- SE values in the control and DEX groups were 3.7 +/- 0.4 microg x ml(-1) and 3.5 +/- 0.2 microg x ml(-1), respectively.",Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19207899/),[μg] / [ml],3.5,25666,DB00633,Dexmedetomidine
,29290034,volume of the central compartment,"The typical values of PK parameters were estimated as 27 L for the volume of the central compartment, 87.6 L for the volume of the peripheral compartment, 38.5 L/h (9.2 mL/min/kg for a 70 kg patient) for systemic clearance and 46.4 L/h for the distribution clearance.",Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29290034/),l,27,27986,DB00633,Dexmedetomidine
,29290034,volume of the peripheral compartment,"The typical values of PK parameters were estimated as 27 L for the volume of the central compartment, 87.6 L for the volume of the peripheral compartment, 38.5 L/h (9.2 mL/min/kg for a 70 kg patient) for systemic clearance and 46.4 L/h for the distribution clearance.",Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29290034/),l,87.6,27987,DB00633,Dexmedetomidine
,29290034,systemic clearance,"The typical values of PK parameters were estimated as 27 L for the volume of the central compartment, 87.6 L for the volume of the peripheral compartment, 38.5 L/h (9.2 mL/min/kg for a 70 kg patient) for systemic clearance and 46.4 L/h for the distribution clearance.",Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29290034/),[l] / [h],38.5,27988,DB00633,Dexmedetomidine
,29290034,systemic clearance,"The typical values of PK parameters were estimated as 27 L for the volume of the central compartment, 87.6 L for the volume of the peripheral compartment, 38.5 L/h (9.2 mL/min/kg for a 70 kg patient) for systemic clearance and 46.4 L/h for the distribution clearance.",Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29290034/),[ml] / [kg·min],9.2,27989,DB00633,Dexmedetomidine
,29290034,distribution clearance,"The typical values of PK parameters were estimated as 27 L for the volume of the central compartment, 87.6 L for the volume of the peripheral compartment, 38.5 L/h (9.2 mL/min/kg for a 70 kg patient) for systemic clearance and 46.4 L/h for the distribution clearance.",Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29290034/),[l] / [h],46.4,27990,DB00633,Dexmedetomidine
,28105598,α2:α1 ratio,It is potent and highly selective for α2-receptors with an α2:α1 ratio of 1620:1.,Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105598/),,1620:1,31057,DB00633,Dexmedetomidine
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,0.7-1.0,32863,DB00633,Dexmedetomidine
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,2.8-4.0,32864,DB00633,Dexmedetomidine
,10655905,target plasma concentrations,"Dexmedetomidine target plasma concentrations were 0.0 (placebo), 0.3 ng ml-1 (low-dex) and 0.6 ng ml-1 (high-dex).",Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10655905/),,0.0,32927,DB00633,Dexmedetomidine
,10655905,target plasma concentrations,"Dexmedetomidine target plasma concentrations were 0.0 (placebo), 0.3 ng ml-1 (low-dex) and 0.6 ng ml-1 (high-dex).",Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10655905/),[ng] / [ml],0.3,32928,DB00633,Dexmedetomidine
,10655905,target plasma concentrations,"Dexmedetomidine target plasma concentrations were 0.0 (placebo), 0.3 ng ml-1 (low-dex) and 0.6 ng ml-1 (high-dex).",Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10655905/),[ng] / [ml],0.6,32929,DB00633,Dexmedetomidine
,27473996,peak remifentanil concentration,Mean peak remifentanil concentration was 7.14ηgmL(-1) at 50min after start of infusion.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],7.14,33193,DB00633,Dexmedetomidine
,27473996,volume of distribution,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[mlkg],268,33194,DB00633,Dexmedetomidine
,27473996,half-life,Mean volume of distribution was 268±40mLkg(-1) and mean half-life was 12.8min.,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),min,12.8,33195,DB00633,Dexmedetomidine
,27473996,Limit of quantification,Limit of quantification was 0.2ηgmL(-1).,Blood concentrations of remifentanil during and after infusion in horses anesthetized with isoflurane and dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473996/),1/[ηgml],0.2,33196,DB00633,Dexmedetomidine
,32166760,Elimination half-lives,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,62.7,37893,DB00633,Dexmedetomidine
,32166760,Elimination half-lives,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,30.1,37894,DB00633,Dexmedetomidine
,32166760,steady-state volumes of distribution,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg],215,37895,DB00633,Dexmedetomidine
,32166760,steady-state volumes of distribution,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg],744,37896,DB00633,Dexmedetomidine
,32166760,clearances,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg·min],21.1,37897,DB00633,Dexmedetomidine
,32166760,clearances,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),[ml] / [kg·min],48.6,37898,DB00633,Dexmedetomidine
,32166760,times to stand,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,47,37899,DB00633,Dexmedetomidine
,32166760,times to stand,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),min,53,37900,DB00633,Dexmedetomidine
,32166760,recovery quality,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),mm,51,37901,DB00633,Dexmedetomidine
,32166760,recovery quality,"Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different.",Pharmacokinetics and clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166760/),mm,61,37902,DB00633,Dexmedetomidine
,33495020,Ramsay sedation score (RSS),We therefore determined the single dose of dexmedetomidine that provided sufficient sedation in 95% (ED95) of children with and without obesity as measured by a minimum Ramsay sedation score (RSS) of 4.,Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33495020/),,4,39469,DB00633,Dexmedetomidine
,33495020,ED95,"The ED95 of dexmedetomidine for adequate sedation in children with obesity was 0.75 μg kg-1 with 95% CI of 0.638-0.780 μg kg-1, overlapping the CI of the ED95 estimate of 0.74 μg kg-1 (95% CI: 0.598-0.779 μg kg-1) for their normal-weight peers.",Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33495020/),[μg] / [kg],0.75,39470,DB00633,Dexmedetomidine
,33495020,ED95,"The ED95 values of dexmedetomidine administered over 10 min were 0.75 and 0.74 μg kg-1 in paediatric subjects with and without obesity, respectively, based on total body weight.",Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33495020/),[μg] / [kg],0.75,39471,DB00633,Dexmedetomidine
,33495020,ED95,"The ED95 values of dexmedetomidine administered over 10 min were 0.75 and 0.74 μg kg-1 in paediatric subjects with and without obesity, respectively, based on total body weight.",Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33495020/),[μg] / [kg],0.74,39472,DB00633,Dexmedetomidine
,26218862,plasma drug clearance,"Dexmedetomidine demonstrated a plasma drug clearance of 657 × (weight/70) mL/min, intercompartmental clearance of 6780 × (weight/70) mL/min, central volume of distribution of 88 × (weight/70) L and peripheral volume of distribution of 112 × (weight/70) L for a typical subject with age >1 month with a cardiopulmonary bypass time of 60 minutes and without right-to-left intracardiac shunt.",Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218862/),[ml] / [min],657,41787,DB00633,Dexmedetomidine
,26218862,intercompartmental clearance,"Dexmedetomidine demonstrated a plasma drug clearance of 657 × (weight/70) mL/min, intercompartmental clearance of 6780 × (weight/70) mL/min, central volume of distribution of 88 × (weight/70) L and peripheral volume of distribution of 112 × (weight/70) L for a typical subject with age >1 month with a cardiopulmonary bypass time of 60 minutes and without right-to-left intracardiac shunt.",Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218862/),[ml] / [min],6780 ×,41788,DB00633,Dexmedetomidine
,26218862,central volume of distribution,"Dexmedetomidine demonstrated a plasma drug clearance of 657 × (weight/70) mL/min, intercompartmental clearance of 6780 × (weight/70) mL/min, central volume of distribution of 88 × (weight/70) L and peripheral volume of distribution of 112 × (weight/70) L for a typical subject with age >1 month with a cardiopulmonary bypass time of 60 minutes and without right-to-left intracardiac shunt.",Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218862/),l,88 ×,41789,DB00633,Dexmedetomidine
,26218862,peripheral volume of distribution,"Dexmedetomidine demonstrated a plasma drug clearance of 657 × (weight/70) mL/min, intercompartmental clearance of 6780 × (weight/70) mL/min, central volume of distribution of 88 × (weight/70) L and peripheral volume of distribution of 112 × (weight/70) L for a typical subject with age >1 month with a cardiopulmonary bypass time of 60 minutes and without right-to-left intracardiac shunt.",Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26218862/),l,112 ×,41790,DB00633,Dexmedetomidine
,10737913,cardiac outputs,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [min],5. 6,45827,DB00633,Dexmedetomidine
,10737913,cardiac outputs,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [min],5.1,45828,DB00633,Dexmedetomidine
,10737913,cardiac outputs,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [min],4.5,45829,DB00633,Dexmedetomidine
,10737913,clearances,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [h],40,45830,DB00633,Dexmedetomidine
,10737913,clearances,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [h],38,45831,DB00633,Dexmedetomidine
,10737913,clearances,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [h],35,45832,DB00633,Dexmedetomidine
,10737913,V(SS),"Dexmedetomidine V(SS) and elimination half-life were 72 (19) L and 1. 9 (0.62) h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),l,72,45833,DB00633,Dexmedetomidine
,10737913,elimination half-life,"Dexmedetomidine V(SS) and elimination half-life were 72 (19) L and 1. 9 (0.62) h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),h,1. 9,45834,DB00633,Dexmedetomidine
,31761600,CNS-to-plasma ratio,"The CNS-to-plasma ratio of vatinoxan concentration was approximately 1:50, whereas the concentrations of dexmedetomidine and levomedetomidine in the CNS were three- to seven-fold of those in plasma.","Concentrations of medetomidine enantiomers and vatinoxan, an α2-adrenoceptor antagonist, in plasma and central nervous tissue after intravenous coadministration in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31761600/),,1,46840,DB00633,Dexmedetomidine
,17122572,V1,"The derived volumes and clearances in the Canadian children were V1 = 0.81 l/kg, V2 = 1.0 l/kg, Cl1 (systemic clearance) = 0.013 l x kg x min, Cl2 = 0.030 l x kg x min.","A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122572/),[l] / [kg],0.81,48047,DB00633,Dexmedetomidine
,17122572,V2,"The derived volumes and clearances in the Canadian children were V1 = 0.81 l/kg, V2 = 1.0 l/kg, Cl1 (systemic clearance) = 0.013 l x kg x min, Cl2 = 0.030 l x kg x min.","A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122572/),[l] / [kg],1.0,48048,DB00633,Dexmedetomidine
,17122572,Cl1 (systemic clearance),"The derived volumes and clearances in the Canadian children were V1 = 0.81 l/kg, V2 = 1.0 l/kg, Cl1 (systemic clearance) = 0.013 l x kg x min, Cl2 = 0.030 l x kg x min.","A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122572/),kg·l·min,0.013,48049,DB00633,Dexmedetomidine
,17122572,Cl2,"The derived volumes and clearances in the Canadian children were V1 = 0.81 l/kg, V2 = 1.0 l/kg, Cl1 (systemic clearance) = 0.013 l x kg x min, Cl2 = 0.030 l x kg x min.","A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122572/),kg·l·min,0.030,48050,DB00633,Dexmedetomidine
,17122572,terminal half-life,The terminal half-life was 110 min (1.8 h).,"A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122572/),min,110,48051,DB00633,Dexmedetomidine
,17122572,terminal half-life,The pharmacokinetics of dexmedetomidine in children are predictable with a terminal half-life of 1.8 h.,"A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122572/),h,1.8,48052,DB00633,Dexmedetomidine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00633,Dexmedetomidine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00633,Dexmedetomidine
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00633,Dexmedetomidine
,30793362,HR,For example at 10 min HR (mean ± s.d.) was 26 ± 2 and 31 ± 5 beats/minute (P = 0.04) and MAP 129 ± 15 and 103 ± 13 mmHg (P<0.001) respectively.,Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793362/),[beats] / [min],26,50566,DB00633,Dexmedetomidine
,30793362,HR,For example at 10 min HR (mean ± s.d.) was 26 ± 2 and 31 ± 5 beats/minute (P = 0.04) and MAP 129 ± 15 and 103 ± 13 mmHg (P<0.001) respectively.,Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793362/),[beats] / [min],31,50567,DB00633,Dexmedetomidine
,18613931,clearance (CL),"Population parameter estimates (between subject variability) were clearance (CL) 39.2 (CV 30.36%) l.h(-1) per 70 kg, central volume of distribution (V1) 36.9 (69.49%) l per 70 kg, inter-compartment clearance (Q) 68.2 (37.6%) l.h(-1) per 70 kg and peripheral volume of distribution (V2) 69.9 (48.6%) l per 70 kg.",Dexmedetomidine disposition in children: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),[l] / [70·h·kg],39.2,50750,DB00633,Dexmedetomidine
,18613931,central volume of distribution (V1),"Population parameter estimates (between subject variability) were clearance (CL) 39.2 (CV 30.36%) l.h(-1) per 70 kg, central volume of distribution (V1) 36.9 (69.49%) l per 70 kg, inter-compartment clearance (Q) 68.2 (37.6%) l.h(-1) per 70 kg and peripheral volume of distribution (V2) 69.9 (48.6%) l per 70 kg.",Dexmedetomidine disposition in children: a population analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),[l] / [70·kg],36.9,50751,DB00633,Dexmedetomidine
,18613931,inter-compartment clearance (Q),"Population parameter estimates (between subject variability) were clearance (CL) 39.2 (CV 30.36%) l.h(-1) per 70 kg, central volume of distribution (V1) 36.9 (69.49%) l per 70 kg, inter-compartment clearance (Q) 68.2 (37.6%) l.h(-1) per 70 kg and peripheral volume of distribution (V2) 69.9 (48.6%) l per 70 kg.",Dexmedetomidine disposition in children: a population analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),[l] / [70·h·kg],68.2,50752,DB00633,Dexmedetomidine
,18613931,peripheral volume of distribution (V2),"Population parameter estimates (between subject variability) were clearance (CL) 39.2 (CV 30.36%) l.h(-1) per 70 kg, central volume of distribution (V1) 36.9 (69.49%) l per 70 kg, inter-compartment clearance (Q) 68.2 (37.6%) l.h(-1) per 70 kg and peripheral volume of distribution (V2) 69.9 (48.6%) l per 70 kg.",Dexmedetomidine disposition in children: a population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),[l] / [70·kg],69.9,50753,DB00633,Dexmedetomidine
,18613931,Clearance,Clearance at birth was 15.55 l.h(-1) per 70 kg and matured with a half-time of 46.5 weeks to reach 87% adult rate by 1 year of age.,Dexmedetomidine disposition in children: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),[-1·l] / [h],15.55,50754,DB00633,Dexmedetomidine
,18613931,half-time,Clearance at birth was 15.55 l.h(-1) per 70 kg and matured with a half-time of 46.5 weeks to reach 87% adult rate by 1 year of age.,Dexmedetomidine disposition in children: a population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),weeks,46.5,50755,DB00633,Dexmedetomidine
,18613931,plasma concentration,h(-1) for 50 min suggested that children arouse from sedation at a plasma concentration of 0.304 mug.l(-1).,Dexmedetomidine disposition in children: a population analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613931/),[μg] / [l],0.304,50756,DB00633,Dexmedetomidine
,17267303,flow rate,"High performance liquid chromatography (HPLC) separation was conducted on an YMC ODS-AQ C(18) column with a flow rate of 0.3 mL/min using a mobile phase comprised of 5 mM ammonium acetate buffer/0.03% formic acid in the solvent mixture of methanol/acetonitrile/water (20:20:60, v/v/v).",Sensitive and specific liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in pediatric plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267303/),[ml] / [min],0.3,53570,DB00633,Dexmedetomidine
,17267303,overall recovery,The overall recovery was 76.6-78.3% for Dex in plasma.,Sensitive and specific liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in pediatric plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267303/),%,76.6-78.3,53571,DB00633,Dexmedetomidine
,34163139,flow rate,"The column was Acquity UPLC BEH C18 column and the mobile phase was acetonitrile-formic acid with gradient mode, and the flow rate was set at 0.4 mL/min.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),[ml] / [min],0.4,59672,DB00633,Dexmedetomidine
,34163139,m/,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,381.10,59673,DB00633,Dexmedetomidine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,246.20,59674,DB00633,Dexmedetomidine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,147.00,59675,DB00633,Dexmedetomidine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,201.10,59676,DB00633,Dexmedetomidine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,94.90,59677,DB00633,Dexmedetomidine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,326.10,59678,DB00633,Dexmedetomidine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,291.10,59679,DB00633,Dexmedetomidine
more,34163139,extraction recovery,"The extraction recovery was more than 79%, and the matrix effect was around 100%.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),%,79,59680,DB00633,Dexmedetomidine
,32986820,V1,"The standardized estimated parameters for an individual of 70 kg was V1 = 35.6 [95% CI, 23.8 to 52.8] l; V2 = 54.7 [34.2 to 81.7] l; CL = 0.56 [0.49 to 0.64] l/min; and F = 7.2 [4.7 to 14.4]%.",A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986820/),l,35.6,61868,DB00633,Dexmedetomidine
,32986820,V2,"The standardized estimated parameters for an individual of 70 kg was V1 = 35.6 [95% CI, 23.8 to 52.8] l; V2 = 54.7 [34.2 to 81.7] l; CL = 0.56 [0.49 to 0.64] l/min; and F = 7.2 [4.7 to 14.4]%.",A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986820/),l,54.7,61869,DB00633,Dexmedetomidine
,32986820,CL,"The standardized estimated parameters for an individual of 70 kg was V1 = 35.6 [95% CI, 23.8 to 52.8] l; V2 = 54.7 [34.2 to 81.7] l; CL = 0.56 [0.49 to 0.64] l/min; and F = 7.2 [4.7 to 14.4]%.",A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986820/),[l] / [min],0.56,61870,DB00633,Dexmedetomidine
,32986820,F,"The standardized estimated parameters for an individual of 70 kg was V1 = 35.6 [95% CI, 23.8 to 52.8] l; V2 = 54.7 [34.2 to 81.7] l; CL = 0.56 [0.49 to 0.64] l/min; and F = 7.2 [4.7 to 14.4]%.",A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986820/),%,7.2,61871,DB00633,Dexmedetomidine
,32158472,plasma clearance,"Noncompartmental analysis yielded descriptive pharmacokinetic estimates: plasma clearance of 0.760 ± 0.155 L/h/kg, steady-state distribution volume of 5.22 ± 2.62 L/kg, and mean residence time of 6.84 ± 3.20 h.",Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32158472/),[l] / [h·kg],0.760,63642,DB00633,Dexmedetomidine
,32158472,steady-state distribution volume,"Noncompartmental analysis yielded descriptive pharmacokinetic estimates: plasma clearance of 0.760 ± 0.155 L/h/kg, steady-state distribution volume of 5.22 ± 2.62 L/kg, and mean residence time of 6.84 ± 3.20 h.",Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32158472/),[l] / [kg],5.22,63643,DB00633,Dexmedetomidine
,32158472,mean residence time,"Noncompartmental analysis yielded descriptive pharmacokinetic estimates: plasma clearance of 0.760 ± 0.155 L/h/kg, steady-state distribution volume of 5.22 ± 2.62 L/kg, and mean residence time of 6.84 ± 3.20 h.",Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32158472/),h,6.84,63644,DB00633,Dexmedetomidine
,30427948,Plasma clearance,Plasma clearance of dexmedetomidine was decreased by 33.3% in the obstructive jaundice group as compared with the control group (0.0068±0.0017 vs. 0.0102±0.0033 L/kg/min; P = 0.002).,The pharmacokinetics of dexmedetomidine in patients with obstructive jaundice: A clinical trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427948/),[l] / [kg·min],0.0068,66334,DB00633,Dexmedetomidine
,30427948,Plasma clearance,Plasma clearance of dexmedetomidine was decreased by 33.3% in the obstructive jaundice group as compared with the control group (0.0068±0.0017 vs. 0.0102±0.0033 L/kg/min; P = 0.002).,The pharmacokinetics of dexmedetomidine in patients with obstructive jaundice: A clinical trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427948/),[l] / [kg·min],0.0102,66335,DB00633,Dexmedetomidine
,30427948,Volume of distribution,Volume of distribution was decreased by 29.2% in the obstructive jaundice group as compared with the control group (1.43±0.58 vs. 2.02±0.84 L/kg; P = 0.041).,The pharmacokinetics of dexmedetomidine in patients with obstructive jaundice: A clinical trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427948/),[l] / [kg],1.43,66336,DB00633,Dexmedetomidine
,30427948,Volume of distribution,Volume of distribution was decreased by 29.2% in the obstructive jaundice group as compared with the control group (1.43±0.58 vs. 2.02±0.84 L/kg; P = 0.041).,The pharmacokinetics of dexmedetomidine in patients with obstructive jaundice: A clinical trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30427948/),[l] / [kg],2.02,66337,DB00633,Dexmedetomidine
,25229603,plasma elimination half-life (Lambda z half-life),"The harmonic mean (SD) plasma elimination half-life (Lambda z half-life) for dexmedetomidine was 20.9 (5.1) min, clearance (Cl) was 0.3 (0.20) L/min/kg, and volume of distribution at steady-state (Vdss ) was 13.7 (7.9) L/kg.",The pharmacokinetics of dexmedetomidine administered as a constant rate infusion in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229603/),min,20.9,67629,DB00633,Dexmedetomidine
,25229603,clearance (Cl),"The harmonic mean (SD) plasma elimination half-life (Lambda z half-life) for dexmedetomidine was 20.9 (5.1) min, clearance (Cl) was 0.3 (0.20) L/min/kg, and volume of distribution at steady-state (Vdss ) was 13.7 (7.9) L/kg.",The pharmacokinetics of dexmedetomidine administered as a constant rate infusion in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229603/),[l] / [kg·min],0.3,67630,DB00633,Dexmedetomidine
,25229603,volume of distribution at steady-state (Vdss ),"The harmonic mean (SD) plasma elimination half-life (Lambda z half-life) for dexmedetomidine was 20.9 (5.1) min, clearance (Cl) was 0.3 (0.20) L/min/kg, and volume of distribution at steady-state (Vdss ) was 13.7 (7.9) L/kg.",The pharmacokinetics of dexmedetomidine administered as a constant rate infusion in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25229603/),[l] / [kg],13.7,67631,DB00633,Dexmedetomidine
,19577876,flow rate,"The mobile phase was a mixture of acetonitrile and 0.5% formic acid solution (30:70, v/v) at a flow rate of 0.2 mL min(-1).",Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577876/),[ml] / [min],0.2,75123,DB00633,Dexmedetomidine
,19577876,m,The detection was performed on a triple quadrupole tandem mass spectrometer in the selected reaction monitoring (SRM) mode using the respective [M+H]+ ions m/z 201.0-->95.1 for DMED and m/z 294.1-->170.1 for the IS.,Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577876/),,201.0,75124,DB00633,Dexmedetomidine
,19577876,m/,The detection was performed on a triple quadrupole tandem mass spectrometer in the selected reaction monitoring (SRM) mode using the respective [M+H]+ ions m/z 201.0-->95.1 for DMED and m/z 294.1-->170.1 for the IS.,Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577876/),,294.1,75125,DB00633,Dexmedetomidine
,34281773,Fe',Anaesthesia was maintained with isoflurane in 50% oxygen (Fe'Iso 1.3-1.5%).,Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),%,1.3-1.5,81318,DB00633,Dexmedetomidine
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.41,81319,DB00633,Dexmedetomidine
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.72,81320,DB00633,Dexmedetomidine
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.52,81321,DB00633,Dexmedetomidine
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.60,81322,DB00633,Dexmedetomidine
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,2.45,81323,DB00633,Dexmedetomidine
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,3.57,81324,DB00633,Dexmedetomidine
,24724965,clearance,Dexmedetomidine clearance was 0.126 l/kg/h [coefficient of variation (CV) 46.6.%] and volume of distribution was 3.37 l/kg (CV 191%).,Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724965/),[l] / [h·kg],0.126,81366,DB00633,Dexmedetomidine
,24724965,volume of distribution,Dexmedetomidine clearance was 0.126 l/kg/h [coefficient of variation (CV) 46.6.%] and volume of distribution was 3.37 l/kg (CV 191%).,Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24724965/),[l] / [kg],3.37,81367,DB00633,Dexmedetomidine
,17693909,duration of infusion,"Average duration of infusion was 18.8 hrs (range, 8-24 hrs).",Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17693909/),h,18.8,83244,DB00633,Dexmedetomidine
,17693909,clearance,"Means (+/-sd) were calculated for the following: clearance, 0.57 (+/-0.14) L/hr per kg; volume of distribution at steady state, 1.53 (+/-0.37) L/kg; and terminal elimination half-life, 2.65 (+/-0.88 hrs)-all similar to published values in adults.",Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17693909/),[l] / [h·kg],0.57,83245,DB00633,Dexmedetomidine
,17693909,volume of distribution at steady state,"Means (+/-sd) were calculated for the following: clearance, 0.57 (+/-0.14) L/hr per kg; volume of distribution at steady state, 1.53 (+/-0.37) L/kg; and terminal elimination half-life, 2.65 (+/-0.88 hrs)-all similar to published values in adults.",Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17693909/),[l] / [kg],1.53,83246,DB00633,Dexmedetomidine
,17693909,terminal elimination half-life,"Means (+/-sd) were calculated for the following: clearance, 0.57 (+/-0.14) L/hr per kg; volume of distribution at steady state, 1.53 (+/-0.37) L/kg; and terminal elimination half-life, 2.65 (+/-0.88 hrs)-all similar to published values in adults.",Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17693909/),h,2.65,83247,DB00633,Dexmedetomidine
,24854710,flow rate,The HPLC resolution was achieved on an Agilent ZORBAX SB-CN column with a gradient elution at a flow rate of 0.5mL/min using a mobile phase of 5-100% of acetonitrile with 0.5% formic acid (mobile phase B) in water (mobile phase A).,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),[ml] / [min],0.5,91375,DB00633,Dexmedetomidine
,24854710,precursor/product transitions,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,201.5,91376,DB00633,Dexmedetomidine
,24854710,precursor/product transitions,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,289.2,91377,DB00633,Dexmedetomidine
,24854710,m/z,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,201.5,91378,DB00633,Dexmedetomidine
,24854710,m/z,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,95.4,91379,DB00633,Dexmedetomidine
,24854710,m/z,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,289.2,91380,DB00633,Dexmedetomidine
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,82.9-87.2,91381,DB00633,Dexmedetomidine
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,85.7-88.4,91382,DB00633,Dexmedetomidine
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,86.2-89.7,91383,DB00633,Dexmedetomidine
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,83.7-88.1,91384,DB00633,Dexmedetomidine
,22030215,length of infusion,"The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours (117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution during the elimination phase, 223 L (35%).",Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22030215/),h,92,98959,DB00633,Dexmedetomidine
,22030215,clearance,"The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours (117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution during the elimination phase, 223 L (35%).",Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22030215/),[l] / [h],39.7,98960,DB00633,Dexmedetomidine
,22030215,elimination half-life,"The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours (117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution during the elimination phase, 223 L (35%).",Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22030215/),h,3.7,98961,DB00633,Dexmedetomidine
,22030215,volume of distribution during the elimination phase,"The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours (117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution during the elimination phase, 223 L (35%).",Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22030215/),l,223,98962,DB00633,Dexmedetomidine
,22030215,clearance at steady state,The geometric mean value for clearance at steady state was 53.1 L/h (55%).,Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22030215/),[l] / [h],53.1,98963,DB00633,Dexmedetomidine
,22030215,elimination half-life,The elimination half-life of H-3 was 9.1 hours (37%).,Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22030215/),h,9.1,98964,DB00633,Dexmedetomidine
,30198929,clearance,"A typical child after liver transplantation with an international normalized ratio (INR) of 1.8 was found to have a whole blood DEX clearance of 52 L/h (95% confidence interval [CI], 31-73 L/h).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),[l] / [h],52,101784,DB00633,Dexmedetomidine
,30198929,intercompartmental clearance,"In addition, intercompartmental clearance was 246 L/h (95% CI, 139-391 L/h), central volume of distribution was 186 L/70 kg (95% CI, 140-301 L/70 kg), and peripheral volume of distribution was 203 L (95% CI, 123-338 L).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),[l] / [h],246,101785,DB00633,Dexmedetomidine
,30198929,central volume of distribution,"In addition, intercompartmental clearance was 246 L/h (95% CI, 139-391 L/h), central volume of distribution was 186 L/70 kg (95% CI, 140-301 L/70 kg), and peripheral volume of distribution was 203 L (95% CI, 123-338 L).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),[l] / [70·kg],186,101786,DB00633,Dexmedetomidine
,30198929,peripheral volume of distribution,"In addition, intercompartmental clearance was 246 L/h (95% CI, 139-391 L/h), central volume of distribution was 186 L/70 kg (95% CI, 140-301 L/70 kg), and peripheral volume of distribution was 203 L (95% CI, 123-338 L).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),l,203,101787,DB00633,Dexmedetomidine
,18546903,Ramsay sedation score,"At the start of laryngoscopy, the patient had a Ramsay sedation score of 6.",[Dexmedetomidine infusion for sedation during awake intubation]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18546903/),,6,103526,DB00633,Dexmedetomidine
,33126702,clearance (CL),Population parameter estimates (population parameter variability%) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) 1.68 L/min/70 kg (63); Q3 0.62 L/min/70 kg (90); volume of distribution in the central compartment (V1) 25.2 L/70 kg (103.9); rapidly equilibrating peripheral compartment (V2) 34.4 L/70 kg (41.8); slow equilibrating peripheral compartment (V3) 65.4 L/70 kg (62).,A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126702/),[l] / [70·kg·min],0.9,105742,DB00633,Dexmedetomidine
,33126702,intercompartmental clearances (Q2),Population parameter estimates (population parameter variability%) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) 1.68 L/min/70 kg (63); Q3 0.62 L/min/70 kg (90); volume of distribution in the central compartment (V1) 25.2 L/70 kg (103.9); rapidly equilibrating peripheral compartment (V2) 34.4 L/70 kg (41.8); slow equilibrating peripheral compartment (V3) 65.4 L/70 kg (62).,A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126702/),[l] / [70·kg·min],1.68,105743,DB00633,Dexmedetomidine
,33126702,Q3,Population parameter estimates (population parameter variability%) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) 1.68 L/min/70 kg (63); Q3 0.62 L/min/70 kg (90); volume of distribution in the central compartment (V1) 25.2 L/70 kg (103.9); rapidly equilibrating peripheral compartment (V2) 34.4 L/70 kg (41.8); slow equilibrating peripheral compartment (V3) 65.4 L/70 kg (62).,A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126702/),[l] / [70·kg·min],0.62,105744,DB00633,Dexmedetomidine
,33126702,volume of distribution in the central compartment (V1),Population parameter estimates (population parameter variability%) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) 1.68 L/min/70 kg (63); Q3 0.62 L/min/70 kg (90); volume of distribution in the central compartment (V1) 25.2 L/70 kg (103.9); rapidly equilibrating peripheral compartment (V2) 34.4 L/70 kg (41.8); slow equilibrating peripheral compartment (V3) 65.4 L/70 kg (62).,A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126702/),[l] / [70·kg],25.2,105745,DB00633,Dexmedetomidine
,33126702,peripheral compartment (V2),Population parameter estimates (population parameter variability%) were clearance (CL) 0.9 L/min/70 kg (36); intercompartmental clearances (Q2) 1.68 L/min/70 kg (63); Q3 0.62 L/min/70 kg (90); volume of distribution in the central compartment (V1) 25.2 L/70 kg (103.9); rapidly equilibrating peripheral compartment (V2) 34.4 L/70 kg (41.8); slow equilibrating peripheral compartment (V3) 65.4 L/70 kg (62).,A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33126702/),[l] / [70·kg],34.4,105746,DB00633,Dexmedetomidine
,31623840,clearance,DEX clearance after CPB was 1240 ml min-1 70 kg-1.,Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623840/),[ml] / [70·kg·min],1240,105803,DB00633,Dexmedetomidine
,31623840,50% maximum clearance,"Age at 50% maximum clearance was approximately 2 days, and that at 90% maximum clearance was 18 days.",Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623840/),,2,105804,DB00633,Dexmedetomidine
,31623840,90% maximum clearance,"Age at 50% maximum clearance was approximately 2 days, and that at 90% maximum clearance was 18 days.",Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623840/),d,18,105805,DB00633,Dexmedetomidine
,31623840,steady-state,Dosing strategies are recommended for steady-state DEX plasma levels ranging from 200 to 1000 pg ml-1.,Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623840/),,200 to 1000,105806,DB00633,Dexmedetomidine
,21288220,V1,"The final pharmacokinetic parameter values were as follows: V1 =63.4 l, V2=41.3 l, V3 =284.3 l, Cl1=0.47×(height/160 cm)(6.42) l/min, Cl2=2.43 l/min and Cl3=0.086 l/min.",Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21288220/),l,63.4,108388,DB00633,Dexmedetomidine
,21288220,V2,"The final pharmacokinetic parameter values were as follows: V1 =63.4 l, V2=41.3 l, V3 =284.3 l, Cl1=0.47×(height/160 cm)(6.42) l/min, Cl2=2.43 l/min and Cl3=0.086 l/min.",Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21288220/),l,41.3,108389,DB00633,Dexmedetomidine
,21288220,V3,"The final pharmacokinetic parameter values were as follows: V1 =63.4 l, V2=41.3 l, V3 =284.3 l, Cl1=0.47×(height/160 cm)(6.42) l/min, Cl2=2.43 l/min and Cl3=0.086 l/min.",Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21288220/),l,284.3,108390,DB00633,Dexmedetomidine
,21288220,Cl1,"The final pharmacokinetic parameter values were as follows: V1 =63.4 l, V2=41.3 l, V3 =284.3 l, Cl1=0.47×(height/160 cm)(6.42) l/min, Cl2=2.43 l/min and Cl3=0.086 l/min.",Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21288220/),[l] / [min],0.47,108391,DB00633,Dexmedetomidine
,21288220,Cl2,"The final pharmacokinetic parameter values were as follows: V1 =63.4 l, V2=41.3 l, V3 =284.3 l, Cl1=0.47×(height/160 cm)(6.42) l/min, Cl2=2.43 l/min and Cl3=0.086 l/min.",Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21288220/),[l] / [min],2.43,108392,DB00633,Dexmedetomidine
,21288220,Cl3,"The final pharmacokinetic parameter values were as follows: V1 =63.4 l, V2=41.3 l, V3 =284.3 l, Cl1=0.47×(height/160 cm)(6.42) l/min, Cl2=2.43 l/min and Cl3=0.086 l/min.",Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21288220/),[l] / [min],0.086,108393,DB00633,Dexmedetomidine
,23839483,clearance,The clearance of dexmedetomidine was 39 (95 % CI 37-41) L/h and volume of distribution 104 (95 % CI 93-115) L.,Population pharmacokinetics of dexmedetomidine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839483/),[l] / [h],39,114512,DB00633,Dexmedetomidine
,23839483,volume of distribution,The clearance of dexmedetomidine was 39 (95 % CI 37-41) L/h and volume of distribution 104 (95 % CI 93-115) L.,Population pharmacokinetics of dexmedetomidine in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23839483/),l,104,114513,DB00633,Dexmedetomidine
,31206433,dose-corrected peak plasma concentration (Cmax),"The average (standard deviation [SD]) dose-corrected peak plasma concentration (Cmax) was 0.011 liter (0.0051), and the median (interquartile range [IQR]) time to reach peak concentration (tmax) was 37 minutes (30-45 minutes).",Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31206433/),l,0.011,115514,DB00633,Dexmedetomidine
,31206433,time to reach peak concentration (tmax),"The average (standard deviation [SD]) dose-corrected peak plasma concentration (Cmax) was 0.011 liter (0.0051), and the median (interquartile range [IQR]) time to reach peak concentration (tmax) was 37 minutes (30-45 minutes).",Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31206433/),min,37,115515,DB00633,Dexmedetomidine
,31743171,CL,"We estimated a CL of 13.4 L/h/70 kg (95% confidence interval, 2.6-24.2 L/h/70 kg) during CPB, compared to 42.1 L/h/70 kg (95% confidence interval, 38.7-45.8 L/h/70 kg) in the historical patients.",Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31743171/),[l] / [70·h·kg],13.4,116388,DB00633,Dexmedetomidine
,31743171,CL,"We estimated a CL of 13.4 L/h/70 kg (95% confidence interval, 2.6-24.2 L/h/70 kg) during CPB, compared to 42.1 L/h/70 kg (95% confidence interval, 38.7-45.8 L/h/70 kg) in the historical patients.",Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31743171/),[l] / [70·h·kg],42.1,116389,DB00633,Dexmedetomidine
,24487703,plasma clearance,Dexmedetomidine plasma clearance was 43% higher in the seizure group compared with the control group (42.7 vs. 29.9 l/h; P = 0.007).,Enzyme-inducing anticonvulsants increase plasma clearance of dexmedetomidine: a pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487703/),[l] / [h],42.7,119473,DB00633,Dexmedetomidine
,24487703,plasma clearance,Dexmedetomidine plasma clearance was 43% higher in the seizure group compared with the control group (42.7 vs. 29.9 l/h; P = 0.007).,Enzyme-inducing anticonvulsants increase plasma clearance of dexmedetomidine: a pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487703/),[l] / [h],29.9,119474,DB00633,Dexmedetomidine
,22280391,apparent volume of distribution of the central compartment,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ml] / [kg],402,121821,DB00633,Dexmedetomidine
,22280391,apparent volume of distribution at steady-state,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ml] / [kg],"1,701",121822,DB00633,Dexmedetomidine
,22280391,clearance,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ml] / [kg·min],6.3,121823,DB00633,Dexmedetomidine
,22280391,terminal half-life,"Weighted mean ± SEM apparent volume of distribution of the central compartment and apparent volume of distribution at steady-state were 402 ± 47 mL/kg and 1,701 ± 200 mL/kg, respectively; clearance and terminal half-life (harmonic mean ± jackknife pseudo-SD) were 6.3 ± 2.8 mL/min/kg and 198 ± 75 minutes, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),min,198,121824,DB00633,Dexmedetomidine
,22280391,area under the plasma concentration curve,"The area under the plasma concentration curve and maximal plasma concentration were 1,061 ± 292 min•ng/mL and 17.6 ± 1.8 ng/mL, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[min·ng] / [ml],"1,061",121825,DB00633,Dexmedetomidine
,22280391,maximal plasma concentration,"The area under the plasma concentration curve and maximal plasma concentration were 1,061 ± 292 min•ng/mL and 17.6 ± 1.8 ng/mL, respectively.",Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-anesthetized cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22280391/),[ng] / [ml],17.6,121826,DB00633,Dexmedetomidine
,31929589,Tmax,Non-compartmental pharmacokinetic analysis revealed a rapid (Tmax = 0.25 ± 0.14 h) and complete IN bioavailability (F = 147.65 ± 49.97%).,"Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),h,0.25,121853,DB00633,Dexmedetomidine
,31929589,bioavailability (F,Non-compartmental pharmacokinetic analysis revealed a rapid (Tmax = 0.25 ± 0.14 h) and complete IN bioavailability (F = 147.65 ± 49.97%).,"Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),%,147.65,121854,DB00633,Dexmedetomidine
,31929589,T1/2el IV,"Elimination half-life was similar between both administration routes (T1/2el IV = 1.47 ± 0.24 h, T1/2el IN = 1.50 ± 0.97 h).","Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),h,1.47,121855,DB00633,Dexmedetomidine
,31929589,T1/2el IN,"Elimination half-life was similar between both administration routes (T1/2el IV = 1.47 ± 0.24 h, T1/2el IN = 1.50 ± 0.97 h).","Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31929589/),h,1.50,121856,DB00633,Dexmedetomidine
,9356115,plasma concentration (Cp),"Dexmedetomidine was infused postoperatively by CCIP for 60 min to eight women, targeting a plasma concentration (Cp) of 600 pg/mL.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),[pg] / [ml],600,122551,DB00633,Dexmedetomidine
,9356115,heart rate,"During the infusion, norepinephrine decreased from 2.1 +/- 0.8 to 0.7 +/- 0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2 nmol/L; heart rate decreased from 76 +/- 15 to 64 +/- 11 bpm; and systolic blood pressure decreased from 158 +/- 23 to 140 +/- 23 mm Hg.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),bpm,76,122552,DB00633,Dexmedetomidine
,9356115,heart rate,"During the infusion, norepinephrine decreased from 2.1 +/- 0.8 to 0.7 +/- 0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2 nmol/L; heart rate decreased from 76 +/- 15 to 64 +/- 11 bpm; and systolic blood pressure decreased from 158 +/- 23 to 140 +/- 23 mm Hg.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),bpm,64,122553,DB00633,Dexmedetomidine
,14616431,absolute bioavailability,"Mean (95% CI) absolute bioavailability after peroral, buccal and intramuscular administration was 16% (12-20%), 82% (73-92%) and 104% (96-112%), respectively.",Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616431/),%,16,122911,DB00633,Dexmedetomidine
,14616431,absolute bioavailability,"Mean (95% CI) absolute bioavailability after peroral, buccal and intramuscular administration was 16% (12-20%), 82% (73-92%) and 104% (96-112%), respectively.",Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616431/),%,82,122912,DB00633,Dexmedetomidine
,14616431,absolute bioavailability,"Mean (95% CI) absolute bioavailability after peroral, buccal and intramuscular administration was 16% (12-20%), 82% (73-92%) and 104% (96-112%), respectively.",Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616431/),%,104,122913,DB00633,Dexmedetomidine
,27027842,maximum concentration,"Median maximum concentration, time to maximum concentration, and bioavailability for detomidine gel following OTM administration were 7.03 ng/mL, 1.00 hour, and 34.52%, respectively; harmonic mean elimination half-life was 0.63 hours.",Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027842/),[ng] / [ml],7.03,123178,DB00633,Dexmedetomidine
,27027842,time to maximum concentration,"Median maximum concentration, time to maximum concentration, and bioavailability for detomidine gel following OTM administration were 7.03 ng/mL, 1.00 hour, and 34.52%, respectively; harmonic mean elimination half-life was 0.63 hours.",Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027842/),h,1.00,123179,DB00633,Dexmedetomidine
,27027842,bioavailability,"Median maximum concentration, time to maximum concentration, and bioavailability for detomidine gel following OTM administration were 7.03 ng/mL, 1.00 hour, and 34.52%, respectively; harmonic mean elimination half-life was 0.63 hours.",Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027842/),%,34.52,123180,DB00633,Dexmedetomidine
,27027842,elimination half-life,"Median maximum concentration, time to maximum concentration, and bioavailability for detomidine gel following OTM administration were 7.03 ng/mL, 1.00 hour, and 34.52%, respectively; harmonic mean elimination half-life was 0.63 hours.",Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027842/),h,0.63,123181,DB00633,Dexmedetomidine
,26233335,bioavailability,Intranasal bioavailability was 82%.,Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233335/),%,82,124283,DB00633,Dexmedetomidine
,7957520,bioavailability,The bioavailability of dexmedetomidine from the TD preparation was 51%.,Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957520/),%,51,129092,DB00633,Dexmedetomidine
,7957520,bioavailability,"However, the bioavailability of dexmedetomidine released from the preparation was 88%.",Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957520/),%,88,129093,DB00633,Dexmedetomidine
,7957520,terminal half-life,The mean terminal half-life was 3.1 h after i.v. and 5.6 h after TD administration.,Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957520/),h,3.1,129094,DB00633,Dexmedetomidine
,7957520,terminal half-life,The mean terminal half-life was 3.1 h after i.v. and 5.6 h after TD administration.,Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957520/),h,5.6,129095,DB00633,Dexmedetomidine
,29661413,bioavailability,Intranasal bioavailability was estimated to be 40.6% (95% CI 34.7-54.4%) and 40.7% (95% CI 36.5-53.2%) for atomisation and drops respectively.,Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661413/),%,40.6,133942,DB00633,Dexmedetomidine
,29661413,bioavailability,Intranasal bioavailability was estimated to be 40.6% (95% CI 34.7-54.4%) and 40.7% (95% CI 36.5-53.2%) for atomisation and drops respectively.,Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661413/),%,40.7,133943,DB00633,Dexmedetomidine
,29661413,half time,"The effect compartment had an equilibration half time 3.3 (95% CI 1.8-4.7) min-1, and the EC50 was estimated to be 903 (95% CI 450-2344) pg ml-1.",Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661413/),1/[min],3.3,133944,DB00633,Dexmedetomidine
,29661413,EC50,"The effect compartment had an equilibration half time 3.3 (95% CI 1.8-4.7) min-1, and the EC50 was estimated to be 903 (95% CI 450-2344) pg ml-1.",Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29661413/),[pg] / [ml],903,133945,DB00633,Dexmedetomidine
,26857784,clearance (CL),"The respective typical values for clearance (CL), V1, V2, Q2, Q3, and V3 were 0.883 L×min(-1), 17.6 L, 51.5 L, 2.37 L×min(-1), 0.517 L×min(-1), and 44.00 L.",Population pharmacokinetics study of dexmedetomidine in Chinese adult patients during spinal anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857784/),[l] / [min],0.883,135432,DB00633,Dexmedetomidine
,26857784,V3,"The respective typical values for clearance (CL), V1, V2, Q2, Q3, and V3 were 0.883 L×min(-1), 17.6 L, 51.5 L, 2.37 L×min(-1), 0.517 L×min(-1), and 44.00 L.",Population pharmacokinetics study of dexmedetomidine in Chinese adult patients during spinal anesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857784/),l,44.00,135433,DB00633,Dexmedetomidine
,27179189,total run time,The total run time was 3.1min and the elution of dexmedetomidine was at 1.24min.,Determination of dexmedetomidine in children's plasma by ultra-performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27179189/),min,3.1,135579,DB00633,Dexmedetomidine
,27179189,elution,The total run time was 3.1min and the elution of dexmedetomidine was at 1.24min.,Determination of dexmedetomidine in children's plasma by ultra-performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27179189/),min,1.24,135580,DB00633,Dexmedetomidine
,27179189,recovery rate,Mean recovery rate of dexmedetomidine in plasma was in the range of 86.7-89.1%.,Determination of dexmedetomidine in children's plasma by ultra-performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27179189/),%,86.7-89.1,135581,DB00633,Dexmedetomidine
,32832543,flow rate,"The plasma was precipitated by acetonitrile, and the two analytes were separated on an Acquity UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm); the mobile phase was acetonitrile and 0.1% formic acid with gradient mode, and the flow rate was 0.4 mL/min.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ml] / [min],0.4,138190,DB00633,Dexmedetomidine
,32832543,m/,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,369.1,138191,DB00633,Dexmedetomidine
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,313.0,138192,DB00633,Dexmedetomidine
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,118.0,138193,DB00633,Dexmedetomidine
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,380.0,138194,DB00633,Dexmedetomidine
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,316.0,138195,DB00633,Dexmedetomidine
,32832543,C max,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2148.59,138196,DB00633,Dexmedetomidine
,32832543,C max,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2100.49,138197,DB00633,Dexmedetomidine
,32832543,t 1/2,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,0.85,138198,DB00633,Dexmedetomidine
,32832543,AUC(0-t),"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],2429.96,138199,DB00633,Dexmedetomidine
,32832543,AUC(0-t),"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],2506.38,138200,DB00633,Dexmedetomidine
,32832543,C max,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2059.15,138201,DB00633,Dexmedetomidine
,32832543,C max,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2837.39,138202,DB00633,Dexmedetomidine
,32832543,t 1/2,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.44,138203,DB00633,Dexmedetomidine
,32832543,t 1/2,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.91,138204,DB00633,Dexmedetomidine
,32832543,AUC(0-t),"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],4971.61,138205,DB00633,Dexmedetomidine
,32832543,AUC(0-t),"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],6770.65,138206,DB00633,Dexmedetomidine
,32832543,t 1/2,"There was no significant change in the pharmacokinetics of parecoxib in groups A and B. C max and AUC(0 - ∞) of valdecoxib in group A were 37.79% and 36.19% higher than those in group B, respectively, and t 1/2 was increased from 2.44 h to 2.91 h.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.44,138207,DB00633,Dexmedetomidine
,32832543,t 1/2,"There was no significant change in the pharmacokinetics of parecoxib in groups A and B. C max and AUC(0 - ∞) of valdecoxib in group A were 37.79% and 36.19% higher than those in group B, respectively, and t 1/2 was increased from 2.44 h to 2.91 h.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.91,138208,DB00633,Dexmedetomidine
,28655497,volume of distribution at steady state,"Median volume of distribution at steady state and terminal half-life were 3169 mL kg-1 (range, 2182-3859 mL kg-1) and 80 minutes (range, 72-88 minutes), respectively.",Pharmacokinetics of dexmedetomidine in isoflurane-anesthetized New Zealand White rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28655497/),[ml] / [kg],3169,139801,DB00633,Dexmedetomidine
,28655497,terminal half-life,"Median volume of distribution at steady state and terminal half-life were 3169 mL kg-1 (range, 2182-3859 mL kg-1) and 80 minutes (range, 72-88 minutes), respectively.",Pharmacokinetics of dexmedetomidine in isoflurane-anesthetized New Zealand White rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28655497/),min,80,139802,DB00633,Dexmedetomidine
,25943714,plasma concentrations,Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia.,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ng] / [ml],1.6-4.5,140789,DB00633,Dexmedetomidine
,25943714,plasma concentrations,Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia.,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ng] / [ml],1.6-2.0,140790,DB00633,Dexmedetomidine
,25943714,volume of the central compartment,Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1).,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],0.80,140791,DB00633,Dexmedetomidine
,25943714,volume of the central compartment,Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1).,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],1.02,140792,DB00633,Dexmedetomidine
,25943714,systemic clearance,"After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1).",Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ml] / [kg·minute],31.5 to 40.3,140793,DB00633,Dexmedetomidine
,25943714,volume of the central compartment,"After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1).",Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],0,140794,DB00633,Dexmedetomidine
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,78,146690,DB00633,Dexmedetomidine
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,162,146691,DB00633,Dexmedetomidine
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,128,146692,DB00633,Dexmedetomidine
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,20,146693,DB00633,Dexmedetomidine
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,23,146694,DB00633,Dexmedetomidine
,24238862,weight-adjusted plasma clearance,"Though there was significant variability in pharmacokinetic variables, group I appeared to have lower weight-adjusted plasma clearance (0.3 vs 0.9 L · h(-1) · kg(-1)) and increased elimination half-life (7.6 vs 3.2 hours) compared with group II.","A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238862/),[l] / [h·kg],0.3,147607,DB00633,Dexmedetomidine
,24238862,weight-adjusted plasma clearance,"Though there was significant variability in pharmacokinetic variables, group I appeared to have lower weight-adjusted plasma clearance (0.3 vs 0.9 L · h(-1) · kg(-1)) and increased elimination half-life (7.6 vs 3.2 hours) compared with group II.","A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238862/),[l] / [h·kg],0.9,147608,DB00633,Dexmedetomidine
,24238862,elimination half-life,"Though there was significant variability in pharmacokinetic variables, group I appeared to have lower weight-adjusted plasma clearance (0.3 vs 0.9 L · h(-1) · kg(-1)) and increased elimination half-life (7.6 vs 3.2 hours) compared with group II.","A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238862/),h,7.6,147609,DB00633,Dexmedetomidine
,24238862,elimination half-life,"Though there was significant variability in pharmacokinetic variables, group I appeared to have lower weight-adjusted plasma clearance (0.3 vs 0.9 L · h(-1) · kg(-1)) and increased elimination half-life (7.6 vs 3.2 hours) compared with group II.","A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238862/),h,3.2,147610,DB00633,Dexmedetomidine
,21318594,absolute bioavailability,"Following intranasal administration, peak plasma concentrations of dexmedetomidine were reached in 38 (15-60) min and its absolute bioavailability was 65% (35-93%) (medians and ranges).",Bioavailability of dexmedetomidine after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318594/),%,65,148902,DB00633,Dexmedetomidine
,32598039,elimination clearance,The typical value of elimination clearance was 0.061 L min-1 and was 35% higher in younger New Zealand White rabbits compared with older animals.,Population analysis to assess the influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in New Zealand White rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32598039/),[l] / [min],0.061,152518,DB00633,Dexmedetomidine
,28828532,Peak plasma concentration,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[μg] / [l],3.75,152587,DB00633,Dexmedetomidine
,28828532,area under the curve to infinity,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],2174,152588,DB00633,Dexmedetomidine
,28828532,area under the curve to infinity,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152589,DB00633,Dexmedetomidine
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[μg] / [l],2.54,152590,DB00633,Dexmedetomidine
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],2174,152591,DB00633,Dexmedetomidine
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152592,DB00633,Dexmedetomidine
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,310,152593,DB00633,Dexmedetomidine
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],1594,152594,DB00633,Dexmedetomidine
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152595,DB00633,Dexmedetomidine
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,158,152596,DB00633,Dexmedetomidine
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,310,152597,DB00633,Dexmedetomidine
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,164,152598,DB00633,Dexmedetomidine
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h],58.6,152599,DB00633,Dexmedetomidine
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h],44.9,152600,DB00633,Dexmedetomidine
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h·kg],0.47,152601,DB00633,Dexmedetomidine
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h·kg],0.64,152602,DB00633,Dexmedetomidine
,29666901,bioavailability,"The mean bioavailability of SC dexmedetomidine was 81% (AUC0-∞ ratio × 100%, range 49-97%).",Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29666901/),%,81,157406,DB00633,Dexmedetomidine
×,29666901,AUC0-∞ ratio,"The mean bioavailability of SC dexmedetomidine was 81% (AUC0-∞ ratio × 100%, range 49-97%).",Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29666901/),%,100,157407,DB00633,Dexmedetomidine
,29666901,peak concentration,"The mean (SD) peak concentration of dexmedetomidine in plasma was 0.3 (0.1) ng/ml, and plasma concentrations associated with sedative effects (i.e., > 0.2 ng/ml) were maintained for 4 h after SC dosing.",Subcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29666901/),[ng] / [ml],0.3,157408,DB00633,Dexmedetomidine
,29782406,clearance (Cl),Population parameters estimates were as follows: mean (between-subject variability): clearance (Cl) (L/h × 70 kg) = 20.8 (27%); central volume of distribution (V1) (L × 70 kg) = 21.9 (20%); peripheral volume of distribution (V2) (L × 70 kg) = 81.2 (21%); and intercompartmental clearance (Q) (L/h × 70 kg) = 75.8 (25%).,Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782406/),[l] / [70·h·kg],20.8,159615,DB00633,Dexmedetomidine
,29782406,central volume of distribution (V1),Population parameters estimates were as follows: mean (between-subject variability): clearance (Cl) (L/h × 70 kg) = 20.8 (27%); central volume of distribution (V1) (L × 70 kg) = 21.9 (20%); peripheral volume of distribution (V2) (L × 70 kg) = 81.2 (21%); and intercompartmental clearance (Q) (L/h × 70 kg) = 75.8 (25%).,Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782406/),l,21.9,159616,DB00633,Dexmedetomidine
,29782406,peripheral volume of distribution (V2),Population parameters estimates were as follows: mean (between-subject variability): clearance (Cl) (L/h × 70 kg) = 20.8 (27%); central volume of distribution (V1) (L × 70 kg) = 21.9 (20%); peripheral volume of distribution (V2) (L × 70 kg) = 81.2 (21%); and intercompartmental clearance (Q) (L/h × 70 kg) = 75.8 (25%).,Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782406/),l,81.2,159617,DB00633,Dexmedetomidine
,29782406,intercompartmental clearance (Q),Population parameters estimates were as follows: mean (between-subject variability): clearance (Cl) (L/h × 70 kg) = 20.8 (27%); central volume of distribution (V1) (L × 70 kg) = 21.9 (20%); peripheral volume of distribution (V2) (L × 70 kg) = 81.2 (21%); and intercompartmental clearance (Q) (L/h × 70 kg) = 75.8 (25%).,Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782406/),[l] / [70·h·kg],75.8,159618,DB00633,Dexmedetomidine
,29782406,IC50,"The PK-PD model predicted a maximum mean arterial blood pressure reduction of 45% with an IC50 of 0.501 ng/ml, and a maximum heart rate reduction of 28.9% with an IC50 of 0.552 ng/ml.",Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782406/),[ng] / [ml],0.501,159619,DB00633,Dexmedetomidine
,29782406,IC50,"The PK-PD model predicted a maximum mean arterial blood pressure reduction of 45% with an IC50 of 0.501 ng/ml, and a maximum heart rate reduction of 28.9% with an IC50 of 0.552 ng/ml.",Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29782406/),[ng] / [ml],0.552,159620,DB00633,Dexmedetomidine
,31806431,distribution clearances,"Typical value (% interindividual variability) for the three volumes (mL kg-1), the metabolic clearance and two distribution clearances (mL minute-1 kg-1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively.",Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),[ml] / [kg·min],2.3,159800,DB00633,Dexmedetomidine
,31806431,distribution clearances,"Typical value (% interindividual variability) for the three volumes (mL kg-1), the metabolic clearance and two distribution clearances (mL minute-1 kg-1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively.",Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),[ml] / [kg·min],42.6,159801,DB00633,Dexmedetomidine
,31806431,distribution clearances,"Typical value (% interindividual variability) for the three volumes (mL kg-1), the metabolic clearance and two distribution clearances (mL minute-1 kg-1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively.",Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),[ml] / [kg·min],5.6,159802,DB00633,Dexmedetomidine
,31806431,second distribution clearance,Hypotension increased the second distribution clearance to 10.6.,Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806431/),,10.6,159803,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],0.16,160504,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],0.31,160505,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],0.63,160506,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],1.25,160507,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],2.5,160508,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],5,160509,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],10,160510,DB00633,Dexmedetomidine
,21521237,maintain plasma concentrations,"Dexmedetomidine was administered intravenously using target-controlled infusions to maintain plasma concentrations of 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, and 20 ng/mL.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],20,160511,DB00633,Dexmedetomidine
,21521237,MAC,"Mean ± SE MAC(iso.0), determined in a previous study conducted under conditions identical to those in this study, was 2.07 ± 0.04.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),,2.07,160512,DB00633,Dexmedetomidine
,21521237,I(max),"Weighted mean ± SE I(max), and IC(50) estimated by the model were 1.76 ± 0.07%, and 1.05 ± 0.08 ng/mL, respectively.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),%,1.76,160513,DB00633,Dexmedetomidine
,21521237,IC(50),"Weighted mean ± SE I(max), and IC(50) estimated by the model were 1.76 ± 0.07%, and 1.05 ± 0.08 ng/mL, respectively.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),[ng] / [ml],1.05,160514,DB00633,Dexmedetomidine
,21521237,MAC(iso),"The lowest MAC(iso) predicted by the model was 0.38 ± 0.08%, illustrating that dexmedetomidine alone is not expected to result in immobility in response to noxious stimulation in cats at any plasma concentration.",Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21521237/),%,0.38,160515,DB00633,Dexmedetomidine
,1358496,time to maximum concentration,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),h,1.6 to 1.7,169292,DB00633,Dexmedetomidine
,1358496,elimination half-life,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),h,1.6 to 2.4,169293,DB00633,Dexmedetomidine
,1358496,apparent total plasma clearance,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),[l] / [h·kg],0.7 to 0.9,169294,DB00633,Dexmedetomidine
,1358496,apparent volume of distribution,"Pharmacokinetic calculations revealed a time to maximum concentration from 1.6 to 1.7 hours, an elimination half-life of 1.6 to 2.4 hours, an apparent total plasma clearance of 0.7 to 0.9 L/hr/kg, and apparent volume of distribution of 2.1 to 2.6 L/kg.",Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358496/),[l] / [kg],2.1 to 2.6,169295,DB00633,Dexmedetomidine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],6.8,171104,DB00633,Dexmedetomidine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.56,171105,DB00633,Dexmedetomidine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.30,171106,DB00633,Dexmedetomidine
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],18.99,171107,DB00633,Dexmedetomidine
,28444697,maximum dexmedetomidine infusion dose,"The median maximum dexmedetomidine infusion dose during the study period was 1.8 μg/(kg·h) (0.5-2.5), and 16/20 infants had a maximum dose >1 μg/(kg·h).",Population Pharmacokinetics of Dexmedetomidine in Infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444697/),[μg] / [h·kg],1.8,171296,DB00633,Dexmedetomidine
>,28444697,maximum dose,"The median maximum dexmedetomidine infusion dose during the study period was 1.8 μg/(kg·h) (0.5-2.5), and 16/20 infants had a maximum dose >1 μg/(kg·h).",Population Pharmacokinetics of Dexmedetomidine in Infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444697/),[μg] / [h·kg],1,171297,DB00633,Dexmedetomidine
,28444697,clearance,"For infants with PMA of 33 to 61 weeks and body weight of 2 to 6 kg, the estimated clearance and volume of distribution were 0.87 to 2.65 L/(kg·h) and 1.5 L/kg, respectively.",Population Pharmacokinetics of Dexmedetomidine in Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444697/),[l] / [h·kg],0.87 to 2.65,171298,DB00633,Dexmedetomidine
,28444697,volume of distribution,"For infants with PMA of 33 to 61 weeks and body weight of 2 to 6 kg, the estimated clearance and volume of distribution were 0.87 to 2.65 L/(kg·h) and 1.5 L/kg, respectively.",Population Pharmacokinetics of Dexmedetomidine in Infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444697/),[l] / [kg],1.5,171299,DB00633,Dexmedetomidine
,18378546,total plasma clearance,"In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively.",Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378546/),[ml] / [kg·min],17.4,173418,DB00633,Dexmedetomidine
,18378546,total plasma clearance,"In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively.",Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378546/),[ml] / [kg·min],17.3,173419,DB00633,Dexmedetomidine
,18378546,volume of distribution at steady state,"In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively.",Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378546/),[l] / [kg],3.8,173420,DB00633,Dexmedetomidine
,18378546,volume of distribution at steady state,"In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively.",Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378546/),[l] / [kg],2.2,173421,DB00633,Dexmedetomidine
,18378546,elimination half-life,"In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively.",Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378546/),min,139,173422,DB00633,Dexmedetomidine
,18378546,elimination half-life,"In the two groups of paediatric patients, the median (range) values for total plasma clearance of dexmedetomidine were 17.4 (14.1-27.6) and 17.3 (9.3-22.5) ml kg(-1) min(-1), for volume of distribution at steady state 3.8 (1.9-4.6) and 2.2 (1.3-2.8) litre kg(-1) (P<0.05), and for elimination half-life 139 (90-198) and 96 (69-140) min (P<0.05), respectively.",Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18378546/),min,96,173423,DB00633,Dexmedetomidine
,16910481,maximum plasma concentration,"The maximum plasma concentration and the plasma concentration in a stable state, which were calculated by pharmacokinetic simulation analysis, were 2.3 ng x ml(-1) and 1.5 ng x ml(-1), respectively.",[Pharmacokinetic simulation of high-dose administration of dexmedetomidine for decubitus treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16910481/),[ng] / [ml],2.3,177048,DB00633,Dexmedetomidine
,16910481,plasma concentration in a stable state,"The maximum plasma concentration and the plasma concentration in a stable state, which were calculated by pharmacokinetic simulation analysis, were 2.3 ng x ml(-1) and 1.5 ng x ml(-1), respectively.",[Pharmacokinetic simulation of high-dose administration of dexmedetomidine for decubitus treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16910481/),[ng] / [ml],1.5,177049,DB00633,Dexmedetomidine
,32889844,time to reach peak serum concentration of DEX (Tmax),The median time to reach peak serum concentration of DEX (Tmax) was significantly shorter in patients who received 1 µg/kg (60 minutes) compared with those who received 0.5 µg/kg (120 minutes; P = .003) and 0.75 µg/kg (120 minutes; P = .004).,Pharmacokinetics and Pharmacodynamics of 3 Doses of Oral-Mucosal Dexmedetomidine Gel for Sedative Premedication in Women Undergoing Modified Radical Mastectomy for Breast Cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889844/),min,60,185157,DB00633,Dexmedetomidine
,32889844,time to reach peak serum concentration of DEX (Tmax),The median time to reach peak serum concentration of DEX (Tmax) was significantly shorter in patients who received 1 µg/kg (60 minutes) compared with those who received 0.5 µg/kg (120 minutes; P = .003) and 0.75 µg/kg (120 minutes; P = .004).,Pharmacokinetics and Pharmacodynamics of 3 Doses of Oral-Mucosal Dexmedetomidine Gel for Sedative Premedication in Women Undergoing Modified Radical Mastectomy for Breast Cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889844/),min,120,185158,DB00633,Dexmedetomidine
,32889844,peak concentration,"The median (first quartile-third quartile) peak concentration of DEX (maximum plasma concentration [Cmax]) in plasma was 0.35 ng/mL (0.31-0.49), 0.37 ng/mL (0.34-0.40), and 0.54 ng/mL (0.45-0.61) in DEX 0.5, DEX 0.75, and DEX 1 groups (P = .082).",Pharmacokinetics and Pharmacodynamics of 3 Doses of Oral-Mucosal Dexmedetomidine Gel for Sedative Premedication in Women Undergoing Modified Radical Mastectomy for Breast Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889844/),[ng] / [ml],0.35,185159,DB00633,Dexmedetomidine
,32889844,peak concentration,"The median (first quartile-third quartile) peak concentration of DEX (maximum plasma concentration [Cmax]) in plasma was 0.35 ng/mL (0.31-0.49), 0.37 ng/mL (0.34-0.40), and 0.54 ng/mL (0.45-0.61) in DEX 0.5, DEX 0.75, and DEX 1 groups (P = .082).",Pharmacokinetics and Pharmacodynamics of 3 Doses of Oral-Mucosal Dexmedetomidine Gel for Sedative Premedication in Women Undergoing Modified Radical Mastectomy for Breast Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889844/),[ng] / [ml],0.37,185160,DB00633,Dexmedetomidine
,32889844,peak concentration,"The median (first quartile-third quartile) peak concentration of DEX (maximum plasma concentration [Cmax]) in plasma was 0.35 ng/mL (0.31-0.49), 0.37 ng/mL (0.34-0.40), and 0.54 ng/mL (0.45-0.61) in DEX 0.5, DEX 0.75, and DEX 1 groups (P = .082).",Pharmacokinetics and Pharmacodynamics of 3 Doses of Oral-Mucosal Dexmedetomidine Gel for Sedative Premedication in Women Undergoing Modified Radical Mastectomy for Breast Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889844/),[ng] / [ml],0.54,185161,DB00633,Dexmedetomidine
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,77.72,185385,DB00633,Dexmedetomidine
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),[ml] / [kg·min],119.41,185386,DB00633,Dexmedetomidine
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,52.73,185387,DB00633,Dexmedetomidine
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),,178.57,185388,DB00633,Dexmedetomidine
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,50.53,185389,DB00633,Dexmedetomidine
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),[ml] / [kg·min],187.24,185390,DB00633,Dexmedetomidine
,26896345,volume of distribution at steady state,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,653,189522,DB00633,Dexmedetomidine
,26896345,volume of distribution at steady state,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,117,189523,DB00633,Dexmedetomidine
,26896345,volume of distribution at steady state,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,491,189524,DB00633,Dexmedetomidine
,26896345,volume of distribution at steady state,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,147,189525,DB00633,Dexmedetomidine
,26896345,clearance (,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,117,189526,DB00633,Dexmedetomidine
,26896345,clearance (,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,491,189527,DB00633,Dexmedetomidine
,26896345,clearance (,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,147,189528,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,296,189529,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,653,189530,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,117,189531,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,491,189532,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,3.0,189533,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,147,189534,DB00633,Dexmedetomidine
,26896345,terminal half-life,"Median (range) volume of the central compartment (mL/kg), volume of distribution at steady state (mL/kg), clearance (mL min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-22.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9) and 52 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4) and 48 (35-60) for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5) and 122 (99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8) and 118 (97-172) for MK-467 in D25M600.","Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896345/),min,462,189535,DB00633,Dexmedetomidine
,29599632,effect-site concentration (Ce),"After the effect-site concentration (Ce) of remifentanil reached 2 ng/mL, propofol TCI induction was started.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[ng] / [ml],2,190627,DB00633,Dexmedetomidine
,29599632,plasma concentration (Cpt),"Anaesthesia induction commenced in the Marsh group at a target plasma concentration (Cpt) of 2 μg/mL, whereas it started in the Schnider group at a target effect-site concentration (Cet) of 2 μg/mL.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],2,190628,DB00633,Dexmedetomidine
,29599632,effect-site concentration (Cet),"Anaesthesia induction commenced in the Marsh group at a target plasma concentration (Cpt) of 2 μg/mL, whereas it started in the Schnider group at a target effect-site concentration (Cet) of 2 μg/mL.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],2,190629,DB00633,Dexmedetomidine
,29599632,target concentration (Ct),"If induction was delayed after 3 min, the target concentration (Ct) was gradually increased to 0.5 μg/mL every 30 sec until successful induction.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],0.5,190630,DB00633,Dexmedetomidine
,29599632,Ct,The Ct for successful induction in the Schnider group was significantly lower than in the Marsh group (3.48 [0.90] versus 4.02 [0.67] μg/mL; P = 0.01).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],3.48,190631,DB00633,Dexmedetomidine
,29599632,Ct,The Ct for successful induction in the Schnider group was significantly lower than in the Marsh group (3.48 [0.90] versus 4.02 [0.67] μg/mL; P = 0.01).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],4.02,190632,DB00633,Dexmedetomidine
,29599632,induction time,The induction time was also shorter in the Schnider group as compared with the Marsh group (134.96 [50.91] versus 161.59 [39.64]) sec; P = 0.02).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),s,134.96,190633,DB00633,Dexmedetomidine
,29599632,induction time,The induction time was also shorter in the Schnider group as compared with the Marsh group (134.96 [50.91] versus 161.59 [39.64]) sec; P = 0.02).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),s,161.59,190634,DB00633,Dexmedetomidine
,9743392,elimination half-lives,"The pharmacokinetics of atipamezole were linear, and elimination half-lives for both drugs were approximately 2 h.",Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743392/),h,2,193123,DB00633,Dexmedetomidine
,30092666,area under curve (AUC),"The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l-1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l-1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h.",Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092666/),[h·ng] / [l],1396.19,194587,DB00633,Dexmedetomidine
,30092666,peak blood concentration (Cmax),"The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l-1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l-1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h.",Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092666/),[ng] / [l],495.50,194588,DB00633,Dexmedetomidine
,30092666,distribution volume (V),"The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l-1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l-1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h.",Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092666/),[l] / [kg],0.68,194589,DB00633,Dexmedetomidine
,30092666,clearance (CL),"The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l-1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l-1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h.",Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092666/),[l] / [h·kg],0.38,194590,DB00633,Dexmedetomidine
,30092666,distribution half-life (t1/2α),"The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l-1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l-1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h.",Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092666/),h,0.05,194591,DB00633,Dexmedetomidine
,30092666,elimination half-life (t1/2β),"The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l-1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l-1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h.",Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30092666/),h,2.53,194592,DB00633,Dexmedetomidine
,22650799,AUC(last),"The AUC(last) of the low-, middle- and high-dose group were 1096.8 ± 119.9 (mean ± SD) ng*h/L, 2643.0 ± 353.2 ng*h/L and 5600.6 ± 411.0 ng*h/L, respectively.",Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22650799/),[h·ng] / [l],1096.8,198327,DB00633,Dexmedetomidine
,22650799,AUC(last),"The AUC(last) of the low-, middle- and high-dose group were 1096.8 ± 119.9 (mean ± SD) ng*h/L, 2643.0 ± 353.2 ng*h/L and 5600.6 ± 411.0 ng*h/L, respectively.",Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22650799/),[h·ng] / [l],2643.0,198328,DB00633,Dexmedetomidine
,22650799,AUC(last),"The AUC(last) of the low-, middle- and high-dose group were 1096.8 ± 119.9 (mean ± SD) ng*h/L, 2643.0 ± 353.2 ng*h/L and 5600.6 ± 411.0 ng*h/L, respectively.",Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22650799/),[h·ng] / [l],5600.6,198329,DB00633,Dexmedetomidine
,18179652,plasma concentration,Mean DMED plasma concentration ranged from 0.23 to 0.47 ng mL(-1) for both groups during the 24-hour CRI with a mean elimination half-life of approximately 0.46 hour.,Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179652/),[ng] / [ml],0.23 to 0.47,199977,DB00633,Dexmedetomidine
,18179652,elimination half-life,Mean DMED plasma concentration ranged from 0.23 to 0.47 ng mL(-1) for both groups during the 24-hour CRI with a mean elimination half-life of approximately 0.46 hour.,Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179652/),h,0.46,199978,DB00633,Dexmedetomidine
,20184754,maximum dose rate,Dexmedetomidine is a selective and potent alpha2-adrenoceptor agonist licensed for use in the sedation of patients initially ventilated in intensive care units at a maximum dose rate of 0.7 mug/kg/h administered for up to 24 hours.,Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184754/),[μg] / [h·kg],0.7,209501,DB00633,Dexmedetomidine
,20184754,maximum dose rate,We describe the case of a 42-year-old Caucasian woman with severe hemorrhagic pancreatitis following laparoscopic cholecystectomy who received dexmedetomidine for 24 consecutive days at a maximum dose rate of 1.9 mug/kg/h.,Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184754/),[μg] / [h·kg],1.9,209502,DB00633,Dexmedetomidine
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,24.7,209966,DB00633,Dexmedetomidine
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,22.2,209967,DB00633,Dexmedetomidine
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,26.5,209968,DB00633,Dexmedetomidine
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,23.7,209969,DB00633,Dexmedetomidine
,32947190,flow rate,"HPLC was performed on an Agilent Poroshell 120 Hilic column (4.6 × 100 mm, 2.7 μm) with isocratic elution at a flow rate of 0.3 mL/min by 0.1% formic acid/acetonitrile (60:40, v/v).",Determination of dexmedetomidine using high performance liquid chromatography coupled with tandem mass spectrometric (HPLC-MS/MS) assay combined with microdialysis technique: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32947190/),[ml] / [min],0.3,215864,DB00633,Dexmedetomidine
,32947190,recoveries,The recoveries of dexmedetomidine in microdialysates were 76.61-93.38%.,Determination of dexmedetomidine using high performance liquid chromatography coupled with tandem mass spectrometric (HPLC-MS/MS) assay combined with microdialysis technique: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32947190/),%,76.61-93.38,215865,DB00633,Dexmedetomidine
,28663042,area under the time-concentration curve,"Median (range) area under the time-concentration curve, absorption rate half-life, maximum concentration, time to maximum concentration and terminal half-life for dexmedetomidine in D25IM and D25MK600IM were 1129 (792-1890) and 924 (596-1649) ng minute mL-1, 4.4 (0.4-15.7) and 2.3 (0.2-8.0) minutes, 10.2 (4.8-16.9) and 17.8 (15.8-73.5) ng mL-1, 17.8 (2.6-44.9) and 5.2 (1.2-15.1) minutes and 62 (52-139) and 50 (31-125) minutes, respectively.","Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male cats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663042/),[min·ng] / [ml],1129,216334,DB00633,Dexmedetomidine
,28663042,terminal half-life,"Median (range) area under the time-concentration curve, absorption rate half-life, maximum concentration, time to maximum concentration and terminal half-life for dexmedetomidine in D25IM and D25MK600IM were 1129 (792-1890) and 924 (596-1649) ng minute mL-1, 4.4 (0.4-15.7) and 2.3 (0.2-8.0) minutes, 10.2 (4.8-16.9) and 17.8 (15.8-73.5) ng mL-1, 17.8 (2.6-44.9) and 5.2 (1.2-15.1) minutes and 62 (52-139) and 50 (31-125) minutes, respectively.","Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663042/),min,17.8,216335,DB00633,Dexmedetomidine
,28663042,terminal half-life,"Median (range) area under the time-concentration curve, absorption rate half-life, maximum concentration, time to maximum concentration and terminal half-life for dexmedetomidine in D25IM and D25MK600IM were 1129 (792-1890) and 924 (596-1649) ng minute mL-1, 4.4 (0.4-15.7) and 2.3 (0.2-8.0) minutes, 10.2 (4.8-16.9) and 17.8 (15.8-73.5) ng mL-1, 17.8 (2.6-44.9) and 5.2 (1.2-15.1) minutes and 62 (52-139) and 50 (31-125) minutes, respectively.","Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663042/),min,5.2,216336,DB00633,Dexmedetomidine
,28663042,terminal half-life,"Median (range) area under the time-concentration curve, absorption rate half-life, maximum concentration, time to maximum concentration and terminal half-life for dexmedetomidine in D25IM and D25MK600IM were 1129 (792-1890) and 924 (596-1649) ng minute mL-1, 4.4 (0.4-15.7) and 2.3 (0.2-8.0) minutes, 10.2 (4.8-16.9) and 17.8 (15.8-73.5) ng mL-1, 17.8 (2.6-44.9) and 5.2 (1.2-15.1) minutes and 62 (52-139) and 50 (31-125) minutes, respectively.","Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663042/),min,62,216337,DB00633,Dexmedetomidine
,28663042,terminal half-life,"Median (range) area under the time-concentration curve, absorption rate half-life, maximum concentration, time to maximum concentration and terminal half-life for dexmedetomidine in D25IM and D25MK600IM were 1129 (792-1890) and 924 (596-1649) ng minute mL-1, 4.4 (0.4-15.7) and 2.3 (0.2-8.0) minutes, 10.2 (4.8-16.9) and 17.8 (15.8-73.5) ng mL-1, 17.8 (2.6-44.9) and 5.2 (1.2-15.1) minutes and 62 (52-139) and 50 (31-125) minutes, respectively.","Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28663042/),min,50,216338,DB00633,Dexmedetomidine
,27004426,EC50,"Mean effect-site EC50 ± SD of propofol for successful i-gel insertion was significantly higher for men than women (5.46 ± 0.26 μg/ml vs. 3.82 ± 0.34 μg/ml, p < 0.01).",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],5.46,222382,DB00633,Dexmedetomidine
,27004426,EC50,"Mean effect-site EC50 ± SD of propofol for successful i-gel insertion was significantly higher for men than women (5.46 ± 0.26 μg/ml vs. 3.82 ± 0.34 μg/ml, p < 0.01).",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],3.82,222383,DB00633,Dexmedetomidine
,27004426,EC50,"Using isotonic regression with a bootstrapping approach, the estimated EC50 (95% confidence interval) of propofol was also higher in men [5.32 (4.45-6.20) μg/ml vs. 3.75 (3.05-4.43) μg/ml].",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],5.32,222384,DB00633,Dexmedetomidine
,27004426,EC50,"Using isotonic regression with a bootstrapping approach, the estimated EC50 (95% confidence interval) of propofol was also higher in men [5.32 (4.45-6.20) μg/ml vs. 3.75 (3.05-4.43) μg/ml].",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],3.75,222385,DB00633,Dexmedetomidine
,27004426,EC95,"The estimated EC95 (95% confidence interval) of propofol in men and women were 5.93 (4.72-6.88) μg/ml and 4.52 (3.02-5.70) μg/ml, respectively.",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],5.93,222386,DB00633,Dexmedetomidine
,27004426,EC95,"The estimated EC95 (95% confidence interval) of propofol in men and women were 5.93 (4.72-6.88) μg/ml and 4.52 (3.02-5.70) μg/ml, respectively.",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],4.52,222387,DB00633,Dexmedetomidine
,31318080,intercompartment distribution clearances,"Typical value (% interindividual variability) for the three-compartment volumes (ml/kg), the metabolic clearance and the two intercompartment distribution clearances (ml min-1 kg-1 ) were 168 (259), 318 (35), 1,425 (18), 12.4 (31), 39.1 (18), and 29.6 (17), respectively.",Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318080/),[ml] / [kg·min],12.4,222691,DB00633,Dexmedetomidine
,31318080,intercompartment distribution clearances,"Typical value (% interindividual variability) for the three-compartment volumes (ml/kg), the metabolic clearance and the two intercompartment distribution clearances (ml min-1 kg-1 ) were 168 (259), 318 (35), 1,425 (18), 12.4 (31), 39.1 (18), and 29.6 (17), respectively.",Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318080/),[ml] / [kg·min],39.1,222692,DB00633,Dexmedetomidine
,31318080,intercompartment distribution clearances,"Typical value (% interindividual variability) for the three-compartment volumes (ml/kg), the metabolic clearance and the two intercompartment distribution clearances (ml min-1 kg-1 ) were 168 (259), 318 (35), 1,425 (18), 12.4 (31), 39.1 (18), and 29.6 (17), respectively.",Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318080/),[ml] / [kg·min],29.6,222693,DB00633,Dexmedetomidine
,34304911,protein binding,Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist with high protein binding of 94%.,Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),%,94,223166,DB00633,Dexmedetomidine
,34304911,protein binding,"Mean protein binding of DEX in the critically ill patients was 90.4% (95% CI, 89.1-91.7), which was 4% lower than that in the healthy control.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),%,90.4,223167,DB00633,Dexmedetomidine
,34304911,systemic clearance (CL),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),[l] / [h],38.6,223168,DB00633,Dexmedetomidine
,34304911,volume of distribution of the central compartment (V2),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),l,32.1,223169,DB00633,Dexmedetomidine
,34304911,volume of distribution of the central compartment (V2),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),[l] / [h],114.5,223170,DB00633,Dexmedetomidine
,34304911,intercompartmental clearance (Q),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),l,32.1,223171,DB00633,Dexmedetomidine
,34304911,intercompartmental clearance (Q),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),[l] / [h],114.5,223172,DB00633,Dexmedetomidine
,34304911,Vd in the peripheral compartment (V3),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),l,95.1,223173,DB00633,Dexmedetomidine
,31362246,AUC0-∞ ratio,"The mean AUC0-∞ ratio between total glucuronides and DMTD in ICU patients receiving infusions (2.09, range 0.55-4.16) appeared lower than the reported value in healthy volunteers receiving bolus intravenous injection (2.86).",Large inter-individual variability in pharmacokinetics of dexmedetomidine and its two major N-glucuronides in adult intensive care unit patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31362246/),,2.09,227849,DB00633,Dexmedetomidine
,31362246,AUC0-∞ ratio,"The mean AUC0-∞ ratio between total glucuronides and DMTD in ICU patients receiving infusions (2.09, range 0.55-4.16) appeared lower than the reported value in healthy volunteers receiving bolus intravenous injection (2.86).",Large inter-individual variability in pharmacokinetics of dexmedetomidine and its two major N-glucuronides in adult intensive care unit patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31362246/),,2.86,227850,DB00633,Dexmedetomidine
,30664276,flow rate,"Separation was achieved with a Waters XBridge C18 column with a flow rate of 0.3 mL/min using a mobile phase comprising 5 mm ammonium acetate buffer with 0.03% formic acid in water and methanol-acetonitrile (50:50, v/v).",An improved ultra-high-performance liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in small volume of pediatric plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30664276/),[ml] / [min],0.3,235003,DB00633,Dexmedetomidine
,31312867,Clearance,"Clearance for a typical neonate, with a post-menstrual age (PMA) of 40 weeks and weight 3.4 kg, was 2.92 L/h.",Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31312867/),[l] / [h],2.92,236410,DB00633,Dexmedetomidine
,31197847,Cmax,"The results showed reduced and delayed absorption of both dexmedetomidine and methadone when administered through an oral transmucosal route, with median (range) Cmax values of 0.82 (0.42-1.49) ng/ml and 13.22 (2.80-52.30) ng/ml, respectively.",Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),[ng] / [ml],0.82,243942,DB00633,Dexmedetomidine
,31197847,Cmax,"The results showed reduced and delayed absorption of both dexmedetomidine and methadone when administered through an oral transmucosal route, with median (range) Cmax values of 0.82 (0.42-1.49) ng/ml and 13.22 (2.80-52.30) ng/ml, respectively.",Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),[ng] / [ml],13.22,243943,DB00633,Dexmedetomidine
,31197847,relative bioavailability,The relative bioavailability was low: 16.34% (dexmedetomidine) and 15.5% (methadone).,Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),%,16.34,243944,DB00633,Dexmedetomidine
,31197847,relative bioavailability,The relative bioavailability was low: 16.34% (dexmedetomidine) and 15.5% (methadone).,Clinical pharmacokinetics of a dexmedetomidine-methadone combination in dogs undergoing routine anaesthesia after buccal or intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197847/),%,15.5,243945,DB00633,Dexmedetomidine
,12067004,distribution half-life,The harmonic mean distribution half-life of dexmedetomidine was 8.6 min and the harmonic mean terminal half-life was 3.14 h.,Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067004/),min,8.6,244947,DB00633,Dexmedetomidine
,12067004,terminal half-life,The harmonic mean distribution half-life of dexmedetomidine was 8.6 min and the harmonic mean terminal half-life was 3.14 h.,Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067004/),h,3.14,244948,DB00633,Dexmedetomidine
,12067004,Steady-state volume of distribution,"Steady-state volume of distribution averaged 173 litres, clearance averaged 48.3 litres h(-1), and the mean residence time averaged 3.86 h.",Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067004/),l,173,244949,DB00633,Dexmedetomidine
,12067004,clearance,"Steady-state volume of distribution averaged 173 litres, clearance averaged 48.3 litres h(-1), and the mean residence time averaged 3.86 h.",Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067004/),[l] / [h],48.3,244950,DB00633,Dexmedetomidine
,12067004,mean residence time,"Steady-state volume of distribution averaged 173 litres, clearance averaged 48.3 litres h(-1), and the mean residence time averaged 3.86 h.",Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067004/),h,3.86,244951,DB00633,Dexmedetomidine
,24762015,volume of distribution at steady-state,"The median volume of distribution at steady-state and terminal half-life were 371 mL/kg (range, 266 to 435 mL/kg) and 31.8 minutes (range, 30.3 to 39.7 minutes), respectively, after administration of 5 μg/kg; 545 mL/kg (range, 445 to 998 mL/kg) and 56.3 minutes (range, 39.3 to 68.9 minutes), respectively, after administration of 20 μg/kg; and 750 mL/kg (range, 514 to 938 mL/kg) and 75.3 minutes (range, 52.2 to 223.3 minutes), respectively, after administration of 50 μg/kg.",Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762015/),[ml] / [kg],371,245723,DB00633,Dexmedetomidine
,24762015,volume of distribution at steady-state,"The median volume of distribution at steady-state and terminal half-life were 371 mL/kg (range, 266 to 435 mL/kg) and 31.8 minutes (range, 30.3 to 39.7 minutes), respectively, after administration of 5 μg/kg; 545 mL/kg (range, 445 to 998 mL/kg) and 56.3 minutes (range, 39.3 to 68.9 minutes), respectively, after administration of 20 μg/kg; and 750 mL/kg (range, 514 to 938 mL/kg) and 75.3 minutes (range, 52.2 to 223.3 minutes), respectively, after administration of 50 μg/kg.",Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762015/),[ml] / [kg],545,245724,DB00633,Dexmedetomidine
,24762015,terminal half-life,"The median volume of distribution at steady-state and terminal half-life were 371 mL/kg (range, 266 to 435 mL/kg) and 31.8 minutes (range, 30.3 to 39.7 minutes), respectively, after administration of 5 μg/kg; 545 mL/kg (range, 445 to 998 mL/kg) and 56.3 minutes (range, 39.3 to 68.9 minutes), respectively, after administration of 20 μg/kg; and 750 mL/kg (range, 514 to 938 mL/kg) and 75.3 minutes (range, 52.2 to 223.3 minutes), respectively, after administration of 50 μg/kg.",Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762015/),min,31.8,245725,DB00633,Dexmedetomidine
,24762015,terminal half-life,"The median volume of distribution at steady-state and terminal half-life were 371 mL/kg (range, 266 to 435 mL/kg) and 31.8 minutes (range, 30.3 to 39.7 minutes), respectively, after administration of 5 μg/kg; 545 mL/kg (range, 445 to 998 mL/kg) and 56.3 minutes (range, 39.3 to 68.9 minutes), respectively, after administration of 20 μg/kg; and 750 mL/kg (range, 514 to 938 mL/kg) and 75.3 minutes (range, 52.2 to 223.3 minutes), respectively, after administration of 50 μg/kg.",Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762015/),min,56.3,245726,DB00633,Dexmedetomidine
,24762015,terminal half-life,"The median volume of distribution at steady-state and terminal half-life were 371 mL/kg (range, 266 to 435 mL/kg) and 31.8 minutes (range, 30.3 to 39.7 minutes), respectively, after administration of 5 μg/kg; 545 mL/kg (range, 445 to 998 mL/kg) and 56.3 minutes (range, 39.3 to 68.9 minutes), respectively, after administration of 20 μg/kg; and 750 mL/kg (range, 514 to 938 mL/kg) and 75.3 minutes (range, 52.2 to 223.3 minutes), respectively, after administration of 50 μg/kg.",Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762015/),[ml] / [kg],750,245727,DB00633,Dexmedetomidine
,24762015,terminal half-life,"The median volume of distribution at steady-state and terminal half-life were 371 mL/kg (range, 266 to 435 mL/kg) and 31.8 minutes (range, 30.3 to 39.7 minutes), respectively, after administration of 5 μg/kg; 545 mL/kg (range, 445 to 998 mL/kg) and 56.3 minutes (range, 39.3 to 68.9 minutes), respectively, after administration of 20 μg/kg; and 750 mL/kg (range, 514 to 938 mL/kg) and 75.3 minutes (range, 52.2 to 223.3 minutes), respectively, after administration of 50 μg/kg.",Pharmacokinetics of dexmedetomidine after intravenous administration of a bolus to cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762015/),min,75.3,245728,DB00633,Dexmedetomidine
,10747239,clearance,"The pharmacokinetics of dexmedetomidine and racemic medetomidine were similar, but clearance of levomedetomidine was more rapid (4.07 +/- 0.69 L/h/kg for LEVO20 and 3.52 +/- 1.03 for LEVO10) than of the other drugs (1.26 +/- 0.44 L/h/kg for MED40, 1.24 +/- 0.48 for DEX20, and 0.97 +/- 0.33 for DEX10).",Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747239/),[l] / [h·kg],4.07,247383,DB00633,Dexmedetomidine
,10747239,clearance,"The pharmacokinetics of dexmedetomidine and racemic medetomidine were similar, but clearance of levomedetomidine was more rapid (4.07 +/- 0.69 L/h/kg for LEVO20 and 3.52 +/- 1.03 for LEVO10) than of the other drugs (1.26 +/- 0.44 L/h/kg for MED40, 1.24 +/- 0.48 for DEX20, and 0.97 +/- 0.33 for DEX10).",Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747239/),,3.52,247384,DB00633,Dexmedetomidine
,10747239,clearance,"The pharmacokinetics of dexmedetomidine and racemic medetomidine were similar, but clearance of levomedetomidine was more rapid (4.07 +/- 0.69 L/h/kg for LEVO20 and 3.52 +/- 1.03 for LEVO10) than of the other drugs (1.26 +/- 0.44 L/h/kg for MED40, 1.24 +/- 0.48 for DEX20, and 0.97 +/- 0.33 for DEX10).",Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747239/),[l] / [h·kg],1.26,247385,DB00633,Dexmedetomidine
,10747239,clearance,"The pharmacokinetics of dexmedetomidine and racemic medetomidine were similar, but clearance of levomedetomidine was more rapid (4.07 +/- 0.69 L/h/kg for LEVO20 and 3.52 +/- 1.03 for LEVO10) than of the other drugs (1.26 +/- 0.44 L/h/kg for MED40, 1.24 +/- 0.48 for DEX20, and 0.97 +/- 0.33 for DEX10).",Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747239/),,1.24,247386,DB00633,Dexmedetomidine
,10747239,clearance,"The pharmacokinetics of dexmedetomidine and racemic medetomidine were similar, but clearance of levomedetomidine was more rapid (4.07 +/- 0.69 L/h/kg for LEVO20 and 3.52 +/- 1.03 for LEVO10) than of the other drugs (1.26 +/- 0.44 L/h/kg for MED40, 1.24 +/- 0.48 for DEX20, and 0.97 +/- 0.33 for DEX10).",Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747239/),,0.97,247387,DB00633,Dexmedetomidine
,31333469,peak plasma concentration,An average peak plasma concentration of 748 ± 30 pg/ml was achieved after 49.6 ± 7.2 min.,Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31333469/),[pg] / [ml],748,252082,DB00633,Dexmedetomidine
,31333469,clearance CL/F,"The population estimates (SE) per 70 kg bodyweight of the apparent pharmacokinetic parameters were clearance CL/F = 0.32 (0.02) L/min, central volume of distribution V1/F = 34.2 (4.9) L, intercompartmental clearance Q2/F = 10.0 (2.2) L/min, and peripheral volume of distribution V2/F = 34.9 (2.3) L.",Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31333469/),[l] / [min],0.32,252083,DB00633,Dexmedetomidine
,31333469,central volume of distribution V1/F,"The population estimates (SE) per 70 kg bodyweight of the apparent pharmacokinetic parameters were clearance CL/F = 0.32 (0.02) L/min, central volume of distribution V1/F = 34.2 (4.9) L, intercompartmental clearance Q2/F = 10.0 (2.2) L/min, and peripheral volume of distribution V2/F = 34.9 (2.3) L.",Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31333469/),l,34.2,252084,DB00633,Dexmedetomidine
,31333469,intercompartmental clearance Q2/F,"The population estimates (SE) per 70 kg bodyweight of the apparent pharmacokinetic parameters were clearance CL/F = 0.32 (0.02) L/min, central volume of distribution V1/F = 34.2 (4.9) L, intercompartmental clearance Q2/F = 10.0 (2.2) L/min, and peripheral volume of distribution V2/F = 34.9 (2.3) L.",Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31333469/),[l] / [min],10.0,252085,DB00633,Dexmedetomidine
,31333469,peripheral volume of distribution V2/F,"The population estimates (SE) per 70 kg bodyweight of the apparent pharmacokinetic parameters were clearance CL/F = 0.32 (0.02) L/min, central volume of distribution V1/F = 34.2 (4.9) L, intercompartmental clearance Q2/F = 10.0 (2.2) L/min, and peripheral volume of distribution V2/F = 34.9 (2.3) L.",Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31333469/),l,34.9,252086,DB00633,Dexmedetomidine
,31333469,Ka,The estimated absorption rate constant was Ka = 0.038 (0.004) min-1.,Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31333469/),1/[min],0.038,252087,DB00633,Dexmedetomidine
,7912045,Tmax,"Dexmedetomidine absorption in CSF after epidural injection was rapid (Tmax = 5-20 min), although pharmacokinetic modeling suggested a biphasic absorption process.",Pharmacokinetics and pharmacodynamics of intraspinal dexmedetomidine in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912045/),min,5-20,255670,DB00633,Dexmedetomidine
,27643584,distribution,"The distribution and elimination half-lives were 8.7 (SD 5.0) and 83.5 (SD 67.5) minutes, respectively.",Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27643584/),min,8.7,259959,DB00633,Dexmedetomidine
,27643584,elimination half-lives,"The distribution and elimination half-lives were 8.7 (SD 5.0) and 83.5 (SD 67.5) minutes, respectively.",Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27643584/),min,83.5,259960,DB00633,Dexmedetomidine
,27643584,maximum concentration,"Mean maximum concentration and body clearance were 12.5 (SD 8.6) ng/mL and 27.9 (SD 13.1) mL/minute/kg, respectively; the mean volume of distribution at steady state was 2,170.8 (SD 1,657.5) mL/kg.",Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27643584/),[ng] / [ml],12.5,259961,DB00633,Dexmedetomidine
,27643584,body clearance,"Mean maximum concentration and body clearance were 12.5 (SD 8.6) ng/mL and 27.9 (SD 13.1) mL/minute/kg, respectively; the mean volume of distribution at steady state was 2,170.8 (SD 1,657.5) mL/kg.",Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27643584/),[ml] / [kg·min],27.9,259962,DB00633,Dexmedetomidine
,27643584,volume of distribution at steady state,"Mean maximum concentration and body clearance were 12.5 (SD 8.6) ng/mL and 27.9 (SD 13.1) mL/minute/kg, respectively; the mean volume of distribution at steady state was 2,170.8 (SD 1,657.5) mL/kg.",Pharmacokinetics and sedative effects of dexmedetomidine in dairy calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27643584/),[ml] / [kg],"2,170.8",259963,DB00633,Dexmedetomidine
,26068206,V1,"A three-compartment allometric model was developed, with the following estimated parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min.",Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068206/),l,1.78,261286,DB00633,Dexmedetomidine
,26068206,V2,"A three-compartment allometric model was developed, with the following estimated parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min.",Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068206/),l,30.3,261287,DB00633,Dexmedetomidine
,26068206,V3,"A three-compartment allometric model was developed, with the following estimated parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min.",Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068206/),l,52.0,261288,DB00633,Dexmedetomidine
,26068206,CL,"A three-compartment allometric model was developed, with the following estimated parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min.",Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068206/),[l] / [min],0.686,261289,DB00633,Dexmedetomidine
,26068206,Q2,"A three-compartment allometric model was developed, with the following estimated parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min.",Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068206/),[l] / [min],2.98,261290,DB00633,Dexmedetomidine
,26068206,Q3,"A three-compartment allometric model was developed, with the following estimated parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min.",Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068206/),[l] / [min],0.602,261291,DB00633,Dexmedetomidine
,15651736,Cmax,"Mean values for kinetic parameters for mature and old ponies were: Cmax (ng/ml) 4.6 and 3.8, t 1/2 (min) 19.8 and 28.9 and AUC (ng.min/ml) 34.5 and 44.3, respectively.",Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651736/),[ng] / [ml],4.6,262952,DB00633,Dexmedetomidine
,15651736,Cmax,"Mean values for kinetic parameters for mature and old ponies were: Cmax (ng/ml) 4.6 and 3.8, t 1/2 (min) 19.8 and 28.9 and AUC (ng.min/ml) 34.5 and 44.3, respectively.",Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651736/),[ng] / [ml],3.8,262953,DB00633,Dexmedetomidine
,15651736,t 1/2,"Mean values for kinetic parameters for mature and old ponies were: Cmax (ng/ml) 4.6 and 3.8, t 1/2 (min) 19.8 and 28.9 and AUC (ng.min/ml) 34.5 and 44.3, respectively.",Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651736/),min,19.8,262954,DB00633,Dexmedetomidine
,15651736,t 1/2,"Mean values for kinetic parameters for mature and old ponies were: Cmax (ng/ml) 4.6 and 3.8, t 1/2 (min) 19.8 and 28.9 and AUC (ng.min/ml) 34.5 and 44.3, respectively.",Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651736/),min,28.9,262955,DB00633,Dexmedetomidine
,15651736,AUC,"Mean values for kinetic parameters for mature and old ponies were: Cmax (ng/ml) 4.6 and 3.8, t 1/2 (min) 19.8 and 28.9 and AUC (ng.min/ml) 34.5 and 44.3, respectively.",Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651736/),[min·ng] / [ml],34.5,262956,DB00633,Dexmedetomidine
,15651736,AUC,"Mean values for kinetic parameters for mature and old ponies were: Cmax (ng/ml) 4.6 and 3.8, t 1/2 (min) 19.8 and 28.9 and AUC (ng.min/ml) 34.5 and 44.3, respectively.",Cardiopulmonary effects and pharmacokinetics of i.v. dexmedetomidine in ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651736/),[min·ng] / [ml],44.3,262957,DB00633,Dexmedetomidine
,22277665,elimination clearance,"The population values (95% confidence interval) for elimination clearance, inter-compartmental clearance, central volume of distribution, and volume of distribution at steady state were 57.0 (42.1, 65.6), 183 (157, 212) litre h(-1), 12.3 (7.6, 17.0), and 132 (96, 189) litre.",Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22277665/),[l] / [h],57.0,262973,DB00633,Dexmedetomidine
,22277665,volume of distribution at steady state,"The population values (95% confidence interval) for elimination clearance, inter-compartmental clearance, central volume of distribution, and volume of distribution at steady state were 57.0 (42.1, 65.6), 183 (157, 212) litre h(-1), 12.3 (7.6, 17.0), and 132 (96, 189) litre.",Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22277665/),l,132,262974,DB00633,Dexmedetomidine
,33576078,Clearance,"Clearance and elimination half-life were 134 ± 67.4 ml/kg/min and 44.3 ± 26.3 min, respectively, in the CRI group, and apparent clearance and half-life were 412 ± 306 ml/kg/min (Cl/F) and 38.9 ± 18.6 min, respectively, in the IM group.",Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576078/),[ml] / [kg·min],134,263122,DB00633,Dexmedetomidine
,33576078,elimination half-life,"Clearance and elimination half-life were 134 ± 67.4 ml/kg/min and 44.3 ± 26.3 min, respectively, in the CRI group, and apparent clearance and half-life were 412 ± 306 ml/kg/min (Cl/F) and 38.9 ± 18.6 min, respectively, in the IM group.",Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576078/),min,44.3,263123,DB00633,Dexmedetomidine
,33576078,apparent clearance,"Clearance and elimination half-life were 134 ± 67.4 ml/kg/min and 44.3 ± 26.3 min, respectively, in the CRI group, and apparent clearance and half-life were 412 ± 306 ml/kg/min (Cl/F) and 38.9 ± 18.6 min, respectively, in the IM group.",Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576078/),[ml] / [kg·min],412,263124,DB00633,Dexmedetomidine
,33576078,Cl/F,"Clearance and elimination half-life were 134 ± 67.4 ml/kg/min and 44.3 ± 26.3 min, respectively, in the CRI group, and apparent clearance and half-life were 412 ± 306 ml/kg/min (Cl/F) and 38.9 ± 18.6 min, respectively, in the IM group.",Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576078/),[ml] / [kg·min],412,263125,DB00633,Dexmedetomidine
,33576078,Cl/F,"Clearance and elimination half-life were 134 ± 67.4 ml/kg/min and 44.3 ± 26.3 min, respectively, in the CRI group, and apparent clearance and half-life were 412 ± 306 ml/kg/min (Cl/F) and 38.9 ± 18.6 min, respectively, in the IM group.",Pharmacokinetics and pharmacodynamics of intravenous continuous rate infusion and repeated intramuscular administration of dexmedetomidine in standing horses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576078/),[ml] / [kg·min],306,263126,DB00633,Dexmedetomidine
,29247451,V1,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),l,60.6,265352,DB00633,Dexmedetomidine
,29247451,V2,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),l,222,265353,DB00633,Dexmedetomidine
,29247451,Cl1,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),[l] / [min],0.825,265354,DB00633,Dexmedetomidine
,29247451,Cl2,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),[l] / [min],4.48,265355,DB00633,Dexmedetomidine
,20305886,plasma concentration,"A pharmacokinetic study provided dexmedetomidine plasma concentration, set to be 3.0 ng*mL(-1).",Hemodynamics and bispectral index (BIS) of dogs anesthetized with midazolam and ketamine associated with medetomidine or dexmedetomidine and submitted to ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305886/),[ng] / [ml],3.0,270806,DB00633,Dexmedetomidine
